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1. INTRODUCTION 
Atherosclerosis is a chronic lipid-driven inflammatory disorder and the domi-
nant underlying cause of cardiovascular disease (CVD) (Libby et al. 2009; 
Wong 2014). Early detection of risk factors and manifestations of athero-
sclerosis is crucial, since CVD accounts for nearly one-third of all deaths world-
wide (Wong 2014). Atherosclerotic lesions occur principally in large and medium-
sized elastic and muscular arteries and can lead to ischemia of the heart, brain or 
extremities (Ross 1999). These arteries expand and contract in response to the 
forces induced by the pulsatile flow, and thus serve both a conduit and a buf-
fering function. Arterial stiffness is a general term for viscoelastic properties 
(elasticity, distensibility, compliance, etc.) of the arteries and is one of the 
earliest detectable signs of the structural and functional alterations of the vessel 
wall (Laurent et al. 2006). Changes in arterial stiffness seem to associate with 
certain hemodynamic, biochemical and inflammatory alterations (Chue et al. 
2010; Jatoi et al. 2007; McEniery et al. 2010a; Wilkinson et al. 2002; Wood-
man et al. 2005). Detailed insights into these associations may help to better 
understand the mechanisms of decline in vascular function, potentially leading 
to CVD. 
Reductions in renal function even in the normal or mildly impaired range 
(estimated glomerular filtration rate (eGFR) 60–130 mL/min/1.73 m2) are inde-
pendently associated with a significant increase in incident CVD (Eisen et al. 
2015). Changes in arterial stiffness could at least partially contribute to early 
functional and structural kidney damage. Since elevated serum creatinine is a 
relatively late marker of renal impairment (Waikar et al. 2012; Wu and Parikh 
2008), a number of potential candidate biomarkers for early detection of renal 
damage have been proposed in recent years (Charlton et al. 2014; Neiman et al. 
2011). Among these are neutrophil gelatinase-associated lipocalin (NGAL), liver-
type fatty acid-binding protein (L-FABP), kidney injury molecule-1 (KIM-1), 
cystatin C (CysC) and fibulin-1 (FBLN-1). Each of these biomarkers have been 
reported to have a potential utility for early identification of acute kidney injury 
(AKI) (Basu et al. 2014; Fiseha 2015; Ichimura et al. 1998, 2004; Mishra et al. 
2003; Neiman et al. 2011; Parr et al. 2015). Moreover, several studies have 
shown that these proteins may also provide a prognostic value for CV morbidity 
and mortality (Cangemi et al. 2011; Carlsson et al. 2013, 2014, Lindberg et al. 
2012, 2014; Matsumori et al. 2012). The role of these biomarkers in athero-
sclerotic patients with an eGFR of more than 60 mL/min/1.73 m2 (i.e. without 
moderate to severe chronic kidney disease (CKD)) is uncertain. However, it can 
be hypothesized that individuals with elevated levels of early renal damage 
markers may also have worse vascular function. Thus, in addition to their role 
in detection of renal impairment, these proteins may also prove useful as sensitive 
reflectors of the interplay between renal and CV dysfunctions. Yet, it must be 
acknowledged that some of these markers have also been suggested to directly 
participate in the development of atherosclerosis, independently of their 
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involvement in renal damage (Argraves et al. 2009; Galis and Khatri 2002; 
Hemdahl et al. 2006; Zhu et al. 2015). 
Although the lipid metabolism-related classical biomarkers (i.e. total 
cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol and triglycerides) and glucose have been estimated for 
decades to assess the risk for CVD, recent analytical developments may enable 
to extend the current metabolic signature for both CVD prognosis and risk 
stratification.  
Metabolomics is an emerging discipline for profiling low molecular weight 
metabolites (including amino acids, peptides, lipids, carbohydrates, nucleic 
acids, fatty acids) in health and disease. Assessment of the metabolome could 
provide insight into the actual metabolic and physiological state of a specific 
cell, organ, or organism. This information allows to gain a more profound under-
standing of the pathogenic mechanisms that lead to CVD, among others. 
Linking metabolomic data to known and validated clinically relevant bio-
chemical and functional biomarkers is essential in unlocking the true potential 
of this discipline. Thus, metabolomic profiling of arterial stiffness and hemo-
dynamics could help to identify novel CVD-related biomarkers and reveal 
potential targets for treatment. 
In the present thesis, patients with symptomatic coronary artery disease 
(CAD) and symptomatic peripheral arterial disease (PAD) were compared. 
CAD and PAD are among the most common clinical manifestations of athero-
sclerosis and serve as major public health problems (Criqui and Aboyans 2015; 
Wong 2014). However, although both of these diseases are related to bio-
chemical and functional abnormalities of the CV system (Abdulhannan et al. 
2012; Hansson 2005; Mattace-Raso et al. 2006; Safar 2007a), a number of 
distinct differences between patients with PAD and CAD should be acknow-
ledged (Grenon et al. 2013; Leng et al. 1995; Rice and Lumsden 2006; 
Shammas 2007). We aimed to study the metabolomic profile of arterial stiffness 
and the role of early biomarkers of renal damage in both of these patient groups 
as well as in clinically healthy subjects. 
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2. REVIEW OF THE LITERATURE 
2.1. Vascular function and cardiovascular disease 
Recent scientific research has shed light on many secrets of the vascular function. 
The knowledge gained from these studies leaves no doubt that arterial stiffness is 
an important early manifestation of CVD (Cecelja and Chowienczyk 2012; 
Laurent et al. 2006; Weber et al. 2004). Yet, the precise mechanisms responsible 
for pathophysiological changes in arterial function still need to be elucidated. 
Unraveling these mechanisms may ultimately yield novel treatment strategies 
for arterial stiffening, which in turn could help prevent the development of CV 
complications. 
 
 
2.1.1. Arterial stiffness and its determinants 
Adverse structural and functional changes within the vessel wall reduce the buf-
fering capacity of arteries and lead to increased arterial stiffness, which is a 
general term for viscoelastic properties (elasticity, distensibility, compliance, 
etc.) of the arteries (Van Bortel et al. 2012; Laurent et al. 2006). The elastic 
properties of conduit vessels vary along the vascular tree; this variation is due to 
molecular, cellular, and histological differences in the wall structure between 
more compliant proximal arteries and stiffer distal arteries (Laurent et al. 2006; 
Nichols and O’Rourke 1998). The pressure load of each heartbeat in large 
conduit vessels is borne mainly by two extracellular matrix proteins: elastin and 
collagen (Townsend et al. 2015a). Because of the anatomic arrangement of the 
compliant elastin fibers and stiffer collagenous fibers, elastin bears most of the 
load at low pressures, whereas collagen is engaged at higher pressures (Town-
send et al. 2015a; Wolinsky and Glagov 1964). Therefore, both proteins serve 
as important structural components of arterial stiffness.  
Besides the passive mechanical effects of elastin and collagen, arterial stiff-
ness is also determined by active functional components, namely nitric oxide 
(NO) bioavailability and vascular smooth muscle tone (Bellien et al. 2010; 
Isabelle et al. 2012; Safar et al. 2001; Sehgel et al. 2013). NO is released by the 
endothelial cells, which form the inner lining of blood vessels, and plays a 
central role in the control of vascular tone (Bellien et al. 2010). Abnormalities 
in the production or actions of NO lead to endothelial dysfunction (ED) as well 
as to abnormal vascular remodeling and stiffening (McEniery et al. 2006; 
Numaguchi et al. 1995; Rudic and Sessa 1999). 
A number of CV risk factors affect arterial stiffness via modulation of its 
structural and/or functional components. Age and blood pressure (BP) are con-
sidered to be the major determinants of vascular elasticity (Avolio et al. 1983; 
Cecelja and Chowienczyk 2009; McEniery et al. 2010b). While elastin fibers 
show the tendency of fragmentation, calcification and degradation in aging, 
collagen concentration in the arterial wall layers (the intima, media and 
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adventitia) increases over time (Kohn et al. 2015; Schlatmann and Becker 
1977). In addition, age-associated arterial stiffening is also caused by non-
enzymatic glycation of collagen (Kohn et al. 2015; Sims et al. 1996). Renal 
function is another important determinant of arterial stiffness both in CKD 
patients (Chue et al. 2010; Townsend 2015b) and in subjects with normal GFR 
(Schillaci et al. 2006). Hypertension influences arterial stiffness and wave 
reflections (McEniery et al. 2010b) mostly via induction of large artery wall 
thickness and remodeling of resistance vessels (Thom 1997). Diminished 
arterial elasticity in diabetes, however, may result from insulin resistance (Van 
Dijk et al. 2003) and the consequences of hyperglycaemia, including the forma-
tion of advanced glycation end-products (Airaksinen et al. 1993; Woodman et 
al. 2005). Although hypercholesterolemia has been positively associated with 
arterial stiffness (Wilkinson et al. 2002), there have also been conflicting 
findings (Dart et al. 2004; Wilkinson and Cockcroft 2007). Other notable 
determinants of arterial stiffness include smoking (Jatoi et al. 2007), obesity 
(Wildman et al. 2003) and poor cardiopulmonary fitness (Boreham et al. 2004). 
 
  
2.1.2. Measures of arterial stiffness and central hemodynamics 
2.1.2.1. Pulse wave analysis 
The arterial pressure waveform is a composite of the forward pressure wave 
created by ventricular contraction and a reflected wave originating from vas-
cular branch points or sites of impedance mismatch (Laurent et al. 2006). Pulse 
wave analysis (PWA) is a computerized process that enables to generate the 
central aortic pressure waveform from the peripheral wave, which is recorded 
noninvasively by applanation tonometry in the radial or carotid artery 
(O’Rourke et al. 2001). From the aortic waveform central systolic BP (CSBP), 
central diastolic BP (CDBP), central pulse pressure (CPP) as well as central 
augmentation pressure (AP) and augmentation index (AIx) can be calculated 
(Figure 1).  
In elastic arteries, the reflected wave returns to the central aorta in diastole 
and, therefore, enhances diastolic perfusion pressure in the coronary circulation 
(Mitchell et al. 2004). Reduction in the buffering capacity of the large arteries, 
however, leads to an early return of reflected waves, and thus to increased 
central aortic pressure (and hence cardiac workload) along with impaired 
coronary artery perfusion (Mitchell 2008; Safar 2007b). An alternative hypo-
thesis, however, states that the magnitude of the AP is mainly determined by the 
arterial reservoir, not wave reflection (Davies et al. 2010; McEniery et al. 2014). 
Although intriguing, this view has also received criticism (Mynard et al. 2012; 
Segers et al. 2012). Whatever its origin, the phenomenon of left ventricular late-
systolic loading can be quantified using the AIx – defined as the difference 
between the second (P2) and first (P1) systolic peaks of the central arterial wave-
form, expressed as a percentage of the CPP (Laurent et al. 2006; Wilkinson et 
al. 2000) (Figure 1). Factors that are known to influence AIx include age, 
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gender, height, heart rate, ejection duration, pulse wave velocity (PWV) and 
mean arterial pressure (MAP) (Hayward and Kelly 1997; Sharman et al. 2009; 
Wilkinson et al. 2000).  
 
 
Figure 1. Central aortic waveform and augmentation index (AIx). Abbreviations: AP, 
augmentation pressure; DBP, diastolic blood pressure; P1, first systolic peak; P2, second 
systolic peak; PP, pulse pressure; SBP, systolic blood pressure. Modified from Hope et 
al. 2002. 
 
 
2.1.2.2. Pulse wave velocity 
The PWV is the rate at which pressure waves travel down the artery. Since the 
waves propagate faster in stiffer vessels than in elastic ones, PWV is a direct 
reflector of arterial stiffness (Bramwell and Hill 1922; Laurent et al. 2006). 
Although it can be obtained in different regions of the arterial tree, the carotid-
femoral PWV (cf-PWV), a measure of aortic stiffness, is considered the ‘gold 
standard’ for arterial stiffness assessment (Van Bortel et al. 2012; Laurent et al. 
2006).  
Different noninvasive methodologies can be used to determine PWV. These 
fall under four categories: 1) devices that use a probe or tonometer to record the 
pulse wave with a transducer, 2) devices using cuffs placed around the limbs or 
the neck, which record the arrival of the pulse wave oscillometrically, 3) ultra-
sonography approaches, and 4) magnetic resonance imaging-based approaches 
(Townsend et al. 2015a). Of these, applanation tonometry is probably the most 
widely used method of cf-PWV measurement. In this method, an arterial 
Dicrotic Notch
Systole Diastole
DBP
SBP (P2)
(P1)
PP
AP
Aortic pressure (mmHg)
Time (ms)
AIx =
AP
PP
x 100
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tonometer is used for recording pressure waveforms; pulse transit time is mea-
sured from the foot of the carotid waveform to that of the femoral waveform 
using sequential recordings referenced to the electrocardiogram (ECG); the 
distance between the two recording sites is measured on body surface and  
cf-PWV is calculated as the ratio between this distance and the pulse transit 
time (Laurent et al. 2006; Millasseau et al. 2005). It is essential to perform 
accurate measurement of BP at the time of cf-PWV assessment because MAP 
and age are the two critical determinants of aortic stiffness (Mattace-Raso et al. 
2010; Townsend et al. 2015a). 
 
 
2.1.3. Prognostic value of arterial stiffness 
Numerous studies have demonstrated that aortic stiffness, measured as cf-PWV, 
independently predicts CV risk and all-cause mortality (Laurent et al. 2001; 
Mitchell et al. 2010; Vlachopoulos et al. 2010a, 2014; Willum-Hansen et al. 
2006). Current European guidelines for the management of arterial hypertension 
state that cf-PWV is a marker of asymptomatic organ damage and can thus help 
reclassify patients at intermediate risk into a higher or lower CV risk in clinical 
practice (Ben-Shlomo et al. 2014; Mancia et al. 2013). The PWV obtained in 
the carotid-radial segment (cr-PWV) does not seem to have a prognostic value 
on its own (Laurent et al. 2006). However, a prospective study in dialysis popu-
lation reported that the ratio of cf-PWV and cr-PWV could be a better prog-
nostic predictor of mortality than cf-PWV alone (Covic and Siriopol 2015; 
Fortier et al. 2015). 
The AIx has also shown independent associations with CV events (Janner et 
al. 2013; Weber et al. 2005; Williams et al. 2006) and all-cause mortality (Janner 
et al. 2013; London et al. 2001). Notably, a systematic review and meta-analysis 
reported that the relative risk of total CV events and all-cause mortality for a 
10% absolute increase of AIx is 1.318 (95% CI 1.093–1.588) and 1.384 (95% 
CI 1.192–1.606), respectively (Vlachopoulos et al. 2010b). Yet, compared to cf-
PWV, the prognostic value of AIx is less well established. 
Lastly, CPP and peripheral PP (PPP) are surrogate measures of arterial 
stiffness, which, together with PP amplification (commonly expressed as 
PPP/CPP), have shown to be related to CV events (Liu et al. 2016; Roman et al. 
2007) and/or mortality (Benetos et al. 2012; Safar et al. 2002; Zhao et al. 2014) 
in various populations. 
 
 
2.1.4. Arginine and asymmetric dimethylarginine 
Arginine (Arg) is an amino acid that is involved in various metabolic pathways 
(Wu and Morris 1998). One of its key functions is to serve as a substrate for a 
family of enzymes named NO synthases (NOS) (Böger 2007; Förstermann et al. 
1994). These enzymes catalyze the conversion of Arg to NO and citrulline 
(Förstermann and Sessa 2012). To date, three different isoforms of NOS have 
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been identified: endothelial NOS (eNOS), inducible NOS and neuronal NOS 
(Förstermann et al. 1994). The NO produced by eNOS in response to stimu-
lation of mechanoreceptors by the shear stress of the flowing blood is critically 
important for the homeostasis of vascular tone, for interactions between the 
arterial wall and circulating blood cells, and for vascular structure (Böger 2007). 
Thus, Arg availability is essential for preserving normal endothelial function. 
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of all 
three NOS isoforms (Kakimoto and Akazawa 1970; Leiper and Nandi 2011; 
Vallance et al. 1992). It is released following the proteolysis of Arg-methylated 
proteins and is removed from the body by a combination of renal excretion and 
metabolism by the dimethylarginine dimethylamino-hydrolase enzymes (Leiper 
and Nandi 2011; Ogawa et al. 1989).  
Since ADMA inhibits NO generation, its elevated levels predispose to ED, 
vasoconstriction and vascular remodeling (Wilcox 2012). Elevated circulating 
levels of ADMA have been reported from various patient populations (Saitoh et 
al. 2003; Surdacki et al. 1999; Yoo and Lee 2001). Furthermore, it indepen-
dently associates with arterial elasticity (Kals et al. 2007) and carotid intima-
media thickness (IMT) progression (Furuki et al. 2008) as well as with CV risk 
and mortality (Abedini et al. 2010; Krzyzanowska et al. 2007; Nijveldt et al. 
2003; Zoccali et al. 2001). In some studies, however, the ADMA/Arg ratio has 
proven to be a better risk marker than ADMA alone (Anderssohn et al. 2012; 
Notsu et al. 2015). 
In the present thesis, we investigated possible relationships between ADMA 
and glycerophospholipids in PAD patients, CAD patients and in clinically 
healthy subjects (Paper IV). 
 
 
2.2. Renal damage and cardiovascular risk 
The CV and renal dysfunctions are intertwined. The data indicate that re-
ductions in renal function even in the normal or mildly impaired range (eGFR 
60–130 mL/min/1.73 m2) are independently associated with a significant increase 
in incident CVD (Eisen et al. 2015). Thus, early functional and structural 
kidney abnormalities may be associated with alterations in arterial function. A 
number of biomarkers with the potential for early detection of renal damage 
have been proposed in recent years, including NGAL, L-FABP, KIM-1, CysC 
and FBLN-1. Besides their potential role as renal biomarkers, some of these 
proteins have also been suggested to be associated with the development of 
atherosclerosis (Argraves et al. 2009; Galis and Khatri 2002; Hemdahl et al. 
2006; Zhu et al. 2015). 
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2.2.1. Neutrophil gelatinase-associated lipocalin 
The NGAL is a small 25 kDa protein that was originally identified in neutrophils, 
but is also expressed in various epithelial cells (e.g. kidney, liver, lungs) in 
response to different pathologic states (Kjeldsen et al. 1993; Singer et al. 2013; 
Xu et al. 1994). NGAL synthesis becomes upregulated during AKI (Mishra et al. 
2003), inflammation (Cowland et al. 2003), infection (Björkqvist et al. 2004), 
and neoplastic development (Bolignano et al. 2010), among others. It is also an 
essential component of the antimicrobial innate immune system, since it modu-
lates neutrophil functions and sequesters iron-loaded bacterial siderophores 
(Nasioudis and Witkin 2015). Interestingly, NGAL synthesis is up-regulated in 
atherosclerosis (Hemdahl et al. 2006) and, via formation of a complex with 
matrix metalloproteinase-9, might participate in plaque rupture (Galis and 
Khatri 2002; Lindberg et al. 2014). Moreover, plasma NGAL correlates with 
CAD severity (Katagiri et al. 2015) and has a prognostic value in patients with 
acute myocardial infarction (MI) (Lindberg et al. 2012) and heart failure 
(Maisel et al. 2011) as well as in the general population (Lindberg et al. 2014). 
 
 
2.2.2. Liver-type fatty acid-binding protein 
The FABPs are a large family of small (~15 kDa) cytosolic proteins that parti-
cipate in the fatty acid uptake, intracellular transport and metabolism (Murphy 
et al. 1996; Ockner et al. 1972; Thumser et al. 2014). The L-FABP is one of the 
members of this family and is expressed not only in the liver but also in the 
intestine, pancreas, stomach, lungs and kidneys (Smathers and Petersen 2011). 
It has high affinity and capacity to bind long-chain fatty acid oxidation products 
and is therefore probably an important endogenous antioxidant (Matsui et al. 
2011; Wang et al. 2005). Plasma and/or urinary levels of L-FABP appear to be 
of a diagnostic and prognostic value for both acute and chronic kidney injury 
(Fiseha 2015; Mou et al. 2012; Parr et al. 2015; Susantitaphong et al. 2013). 
Moreover, a study in subjects with type 2 diabetes and CKD suggested that 
simultaneous measurement of urinary L-FABP and albumin-to-creatinine ratio 
may be useful to assess cardiac damage in these patients (Maeda et al. 2014). In 
cases of acute coronary syndrome, elevated L-FABP levels can help identify 
individuals at high risk for future CV events (Matsumori et al. 2012).  
 
 
2.2.3. Kidney injury molecule-1 
The KIM-1 is a type 1 transmembrane protein that is not detectable in normal 
kidney tissue but is highly expressed in dedifferentiated proximal tubule epithelial 
cells after ischemic (Ichimura et al. 1998) or toxic (Ichimura et al. 2004) injury. 
Interestingly, it facilitates clearance of the apoptotic debris from the tubular 
lumen, and is therefore unique in being the first non-myeloid phosphatidylserine 
receptor that transforms epithelial cells into semi-professional phagocytes 
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(Bonventre 2009; Ichimura et al. 2008). A study in mice demonstrated that by 
facilitating the phagocytic process, KIM-1 might have a protective anti-
inflammatory role in the early stages of AKI (Yang et al. 2015). Another work 
in a rat MI model showed that KIM-1 gene expression was dramatically up-
regulated at 1 week in a post-MI kidney (Lekawanvijit et al. 2012). Most 
importantly, KIM-1 has demonstrated a diagnostic value as an early biomarker 
of AKI in different clinical settings (Han et al. 2009; Medić et al. 2015; Yang et 
al. 2016) and was independently associated with CV mortality and incidence of 
heart failure in a community-based cohort of elderly men (Carlsson et al. 2013, 
2014). 
 
 
2.2.4. Cystatin C 
The CysC is a 13 kDa endogenous cysteine proteinase inhibitor that is freely 
filtrated through the glomeruli and has been reported superior to creatinine in 
identifying renal dysfunction at eGFR levels above 60 mL/min/1.73 m2 (Dhar-
nidharka et al. 2002; Grubb and Löfberg 1982; Luo et al. 2015). Moreover, 
serum CysC helps to improve diagnostic precision for AKI for both adults and 
children (Basu et al. 2014; Peco-Antić et al. 2013). A meta-analysis of 38,854 
participants showed that elevated serum CysC levels independently associate 
with excessive CV and all-cause mortality risk in the general populations with 
age over 40 years (Luo et al. 2015). Similarly, a study in middle-aged individuals 
without a history of CVD reported CysC to be a better risk marker for CV 
prognosis than creatinine-based GFR (Svensson-Färbom et al. 2014). The 
association between serum CysC and CV events is not entirely explained by the 
renal dysfunction and might be partially mediated by inflammation (Koenig et 
al. 2005; Salgado et al. 2013). Indeed, high CysC concentrations have been 
previously related to both inflammation (Knight et al. 2004; Leung-Tack et al. 
1990) and atherosclerosis (Zhu et al. 2015). However, contrary results have also 
been observed (Albert et al. 2001; Grubb et al. 2011). 
 
 
2.2.5. Fibulin-1 
The FBLN-1 is an extracellular matrix glycoprotein that binds fibronectin, elastin, 
and proteoglycans and is one of the few extracellular matrix proteins normally 
present at high concentrations in blood (Argraves et al. 1989; Cangemi et al. 
2011). It is notably expressed in the dermis, lung, heart valves and in the blood 
vessel wall, and seems to be crucial in embryonic development (Miosge et al. 
1996; Roark et al. 1995). Mice lacking FBLN-1 gene expression die perinatally 
due to a combination of blood loss and renal and respiratory impairments (Kostka 
et al. 2001). Interestingly, plasma profiling has revealed that FBLN-1 could 
serve as a potential indicator to monitor kidney malfunction or kidney damage 
(Neiman et al. 2011). Since prominent deposition of FBLN-1 has been found 
within atherosclerotic lesions and clots, the protein may also play a role in 
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processes leading to the progression and thrombotic complications of athero-
sclerosis (Argraves et al. 2009). Furthermore, FBLN-1 correlates with aortic 
stiffness and predicts mortality in patients with type 2 diabetes (Cangemi et al. 
2011; Laugesen et al. 2013). In CAD patients without diabetes, a relationship 
between aortic AIx and plasma FBLN-1 was recently found (Hansen and 
Rasmussen 2015). 
In the current thesis, we aimed to measure the serum/urinary levels of the 
above-mentioned early biomarkers of renal damage and to evaluate their 
association with arterial stiffness and inflammation in patients with CAD and in 
clinically healthy subjects (Papers I and II). 
 
 
2.3. Inflammation and cardiovascular risk 
Inflammation is considered critical for the initiation and progression of athero-
sclerosis. Moreover, a significant decrease in aortic stiffness following a 
reduction in inflammation has been reported (Mäki-Petäjä et al. 2006). However, 
whether targeted inhibition of inflammation reduces the risk of CV events still 
remains unproven. Two ongoing randomized controlled trials (RCTs) address 
this uncertainty and will hopefully provide good evidence for supporting or 
rejecting the inflammatory hypothesis of atherothrombosis (Ridker 2009a; 
Ridker et al. 2011). 
 
 
2.3.1. Inflammation-related biomarkers 
Interleukin-6 (IL-6) and C-reactive protein (CRP). The IL-6 is a proinflam-
matory cytokine that was originally cloned in 1986 (Hirano et al. 1986). It 
exerts its pleiotropic biological actions via a complex consisting of a specific 
IL-6 receptor (IL-6R) and a signal transducing subunit (glycoprotein 130) 
(Peters et al. 1996). The soluble form of IL-6R is also able to bind with this 
cytokine, after which the complex can attach to glycoprotein 130. This process 
is called trans-signaling and it leads to activation of cells that lack membrane-
bound IL-6R (Peters et al. 1996; Rose-John 2012).  
The IL-6 plays critical roles in the immune response and hematopoiesis 
(Hirano et al. 1986, 1990). Moreover, it is a major regulator of acute phase 
protein synthesis in human hepatocytes, since it stimulates C-reactive protein, 
serum amyloid A, fibrinogen, haptoglobin and hepcidin production and inhibits 
the synthesis of transferrin, fibronectin and albumin (Castell et al. 1989), among 
others. Thus, IL-6 is an upstream regulator that plays a central role in propa-
gating the downstream inflammatory response and might therefore make a causal 
contribution to the development of atherosclerosis (Hartman and Frishman 
2014). Large amounts of IL-6 have been found in arterial atherosclerotic lesions 
(Rus et al. 1996; Seino et al. 1994) and its circulating concentrations link to 
both ED (Esteve et al. 2007) and arterial stiffness (Mahmud and Feely 2005). 
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Furthermore, an increased CV risk has been reported in apparently healthy men 
(Ridker et al. 2000a) and women (Ridker et al. 2000b) with elevated levels of 
IL-6 and high-sensitivity CRP (hsCRP). Mendelian randomization studies have 
suggested that on the basis of genetic evidence, IL-6 seems to have a causal role 
in development of CVD, whereas CRP does not (Casas et al. 2006; Hingorani 
and Casas 2012; Kivimäki et al. 2007; Wensley et al. 2011). Therefore, IL-6, 
rather than CRP, has emerged as a potential therapeutic target in atherothrom-
botic disease, although moving even further upstream to the interleukin-1 
signaling pathway might be needed for efficient immune modulation and 
atherothrombotic protection (Ridker 2016). 
As noted above, CRP is produced by hepatocytes largely under regulatory 
control of inflammatory cytokines including IL-6 and tumor necrosis factor-α 
(TNF-α) (Ridker 2009b). It is a homopentameric protein with Ca-binding spe-
cificity for phosphocholine and was first discovered in 1930 (Tillett and Francis 
1930; Volanakis 2001). The CRP synthesis is rapidly upregulated in response to 
inflammation and the protein participates in complement activation as well as in 
innate immune function (Du Clos 2000; Ridker 2016). Interestingly, CRP has 
been found to induce expression of adhesion molecules (Pasceri et al. 2000) and 
plasminogen activator inhibitor-1 (PAI-1) (Devaraj et al. 2003) by human 
endothelial cells. Furthermore, it also seems to directly decrease eNOS 
expression/bioactivity (Venugopal et al. 2002) and prostacyclin release 
(Venugopal et al. 2003) from these cells. Although these findings suggest that 
CRP might play a causal role in atherogenesis, the above-mentioned more 
recent Mendelian randomization studies do not support this view (Kivimäki et 
al. 2007; Wensley et al. 2011). Moreover, it has been demonstrated that intact 
authentic human CRP itself does not have any detectable proinflammatory 
effects in healthy adults (Lane et al. 2014). Nevertheless, hsCRP can still be a 
clinically useful tool to assess risk in patients with an unusual or moderate CVD 
risk profile (Perk et al. 2012) and might help to determine whether to initiate 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy for 
primary prevention in selected patients (Stone et al. 2014). Like IL-6, hsCRP 
levels predict future vascular risk in apparently healthy populations (Ridker et 
al. 2000a; Ridker et al. 2000b) and associate with both ED (De Haro et al. 
2008) and arterial stiffness (Kampus et al. 2006; Mahmud and Feely 2005). 
Also, since there is no clinically approved assay for IL-6, and because its 
measurement is more complicated than that of hsCRP (e.g. circadian variation, 
shorter half-life, post-prandial effects) (Ridker 2016), the latter remains the 
biomarker of choice to assess low-grade inflammation in clinical practice. 
Myeloperoxidase (MPO) and ferritin. Several other proteins, besides IL-6 
and hsCRP, have shown value as inflammatory biomarkers in CVD (Ikonomidis 
et al. 2012; Koenig et al. 2005). MPO, a member of the heme peroxidase super-
family, is secreted primarily on polymorphonuclear neutrophil activation and 
degranulation and participates in both innate and acquired immunity (Lehrer et 
al. 1969; Odobasic et al. 2013, 2016). The protein was first isolated in 1941 
(Agner 1941) and has a principal role in promotion of oxidative stress (OxS) at 
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sites of inflammation (Nicholls and Hazen 2005; Zhang et al. 2002). It is highly 
expressed in atherosclerotic lesions (Daugherty et al. 1994) and has been shown 
to initiate lipid peroxidation (Zhang et al. 2002), to promote ED (Eiserich et al. 
2002) and to contribute to plaque rupture via matrix metalloproteinase activa-
tion in the artery wall (Fu et al. 2001). Increased circulating levels of this protein 
have been reported in patients with CAD, and particularly in those experiencing 
acute coronary syndrome (Ndrepepa et al. 2008). Furthermore, MPO does not 
only independently predict CV mortality in both of these populations (Baldus et 
al. 2003; Heslop et al. 2010; Mocatta et al. 2007) but also helps to identify 
healthy individuals with higher future risk of CAD (Meuwese et al. 2007). 
Although previous data have suggested a protective effect of MPO deficiency 
against MI and atheroma (Kutter et al. 2000), convincing evidence of a causal 
relation between MPO and CVD is still lacking. 
The participation of transition metal ions such as iron in the formation of 
different reactive species has also long been recognized (Halliwell and Gutteridge 
1984). Ferritin is the main iron storage compound, and hence a biomarker of 
iron status, in the body and is present mainly in the reticuloendothelial cells of 
the liver, spleen, and bone marrow (Walters et al. 1973). It is an acute phase 
protein that becomes highly expressed in conditions marked by uncontrolled 
cellular proliferation, excessive production of toxic oxygen reactive species and 
inflammation (Konijn and Hershko 1977; Sung et al. 2012). Numerous studies 
have linked high serum ferritin levels to morbidity and mortality in different 
clinical settings (Abril-Ulloa et al. 2014; Kalantar-Zadeh et al. 2001; Maiwall et 
al. 2014). It is associated with higher coronary plaque volume (Battes et al. 2014) 
and MI risk (Salonen et al. 1992) for patients with CAD and with mortality 
(DePalma et al. 2010) for patients with PAD, whereas in the general population 
it has been related to both the presence of coronary artery calcium (Sung et al. 
2012) and early death (Ellervik et al. 2014). However, the mechanisms behind 
the associations between serum ferritin and different low-grade inflammatory 
diseases are still in dispute (Kell and Pretorius 2014). 
In the present thesis, the serum levels of IL-6 (Papers II–IV), hsCRP 
(Papers I–IV), MPO (Papers II and III) and ferritin (Paper II) were determined 
and their possible relationship with early biomarkers of renal damage and/or 
low molecular weight metabolites was examined. 
 
 
2.3.2. Adipokines and plasminogen activator inhibitor-1 
The role of adipose tissue in low-grade inflammation and metabolism is increa-
singly acknowledged. Since the discovery of leptin (Zhang et al. 1994), 
hundreds of other bioactive molecules, generally named adipokines, have been 
shown to be secreted by this tissue (Fasshauer and Blüher 2015). The majority 
of adipokines exert pro-inflammatory effects on the CV system, whereas a small 
number of anti-inflammatory adipokines have been recognized as CV protectors 
(Ohashi et al. 2014).  
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Adiponectin is a major anti-inflammatory adipocyte-secreted protein that 
acts via two receptor isoforms, adiponectin receptor 1 and 2 (Scherer et al. 1995; 
Yamauchi et al. 2003). The protein itself has three isoforms (low-, medium- and 
high molecular weight) with distinct biological effects (Hattori et al. 2008; 
Kobayashi et al. 2004) and the percentage of each isoform per total adiponectin 
can vary in different populations (Aso et al. 2006; Rizza et al. 2010). While 
plasma levels of most proteins produced by adipose tissue tend to elevate along 
with an increase in total body fat mass, adiponectin levels are paradoxically 
reduced in obesity (Arita et al. 1999). There is also a clear gender difference in 
circulating adiponectin concentrations (Böttner et al. 2004), which can be at 
least partially explained by the inhibition of its secretion from adipocytes by 
testosterone (Xu et al. 2005).  
Adiponectin acts as an endogenous insulin sensitizer by stimulating adeno-
sine monophosphate-activated protein kinase (Yamauchi et al. 2002) and is 
inversely associated with type 2 diabetes (Koenig et al. 2006; Lindberg et al. 
2015). Also, it exerts multiple beneficial effects on the CV system through direct 
and indirect actions on both cardiac and vascular cells (Caselli et al. 2014; 
Ghantous et al. 2015). Adiponectin regulates vascular homeostasis via adeno-
sine monophosphate-activated protein kinase-eNOS and cyclooxygenase-2/ 
prostacyclin regulatory pathways within endothelial cells and is able to confer 
an anti-inflammatory phenotype in macrophages (Ouchi et al. 2012). Low 
circulating levels of adiponectin have been reported to be associated with 
impaired endothelium-dependent vasorelaxation (Okui et al. 2008; Ouchi et al. 
2003), arterial stiffness (Youn et al. 2013), left ventricular hypertrophy (Pääkkö 
et al. 2010) and hypertension (Imatoh et al. 2008). Interestingly, however, a meta-
analysis with 23,717 participants showed that, in the general population, serum 
adiponectin levels were positively related to the risk of ischemic stroke and did 
not associate with an increased or decreased risk of CVD (Hao et al. 2013). The 
authors speculated that differences in the levels of adiponectin isoforms with 
variable pathophysiological roles may partially underlie those somewhat un-
expected results (Hao et al. 2013). 
Leptin, resistin and PAI-1. The biological effects of leptin, resistin and 
PAI-1 are generally considered to be pro-inflammatory under pathophysio-
logical conditions. Leptin is produced primarily in the adipocytes and acts 
through its receptor (Tartaglia et al. 1995) which is present in a wide range of 
tissues in several alternatively spliced forms (Chen et al. 1999; Margetic et al. 
2002). This adipokine modulates the CV, immune, nervous, and reproductive 
systems (Abel and Sweeney 2012; Lord et al. 1998; Margetic et al. 2002), but 
its key task is the regulation of appetite (Brunner et al. 1997) and energy 
homeostasis (Tuominen et al. 1997). In obesity, despite elevated circulating 
leptin concentrations, a dysregulation of energy balance is observed, suggesting 
that obese people become resistant to this adipokine (Bjørbæk et al. 1999; 
Freitas Lima et al. 2015). Interestingly, however, the resistance appears to be 
selective, since insulin desensitizing and pro-inflammatory effects of leptin are 
maintained (Freitas Lima et al. 2015; Mark 2013; Mark et al. 2002). Indeed, 
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increased circulating leptin levels have been associated with insulin resistance 
(Fischer et al. 2002), hypertension (Correia et al. 2001), arterial stiffness 
(Windham et al. 2010), myocardial wall thickness (Paolisso et al. 1999) and 
atherosclerosis (Reilly et al. 2004; Schäfer et al. 2004), among others. There-
fore, leptin can be regarded as a biomarker linking obesity and insulin resistance 
with various CV pathologies.  
In 2001, another pro-inflammatory adipocyte-derived hormone, resistin, 
was discovered and linked with obesity and diabetes in mice (Steppan et al. 
2001a). However, human resistin is primarily expressed in and secreted from 
monocytes (Lee et al. 2014; Patel et al. 2003) and is sometimes referred to as a 
protein “found in the inflammatory zone” (Fantuzzi 2005). It is a 12.5 kDa 
cysteine rich peptide (Steppan et al. 2001b) whose receptor in humans was 
unknown until recently, when adenylyl cyclase-associated protein 1 was shown 
to mediate the pro-inflammatory effects of resistin in vitro and in vivo (Lee et 
al. 2014). Interestingly, resistin is able to strongly up-regulate IL-6 and TNF-α 
expression and enhance its own activity by a positive feedback (Bokarewa et al. 
2005). Its independent association with heart failure incidence and CV risk 
(Frankel et al. 2009; Menzaghi et al. 2013; Muse et al. 2015) could be explained 
by its pro-inflammatory and pro-atherogenic effects (Cho et al. 2010; Reilly et 
al. 2005). Moreover, resistin has been reported to associate with arterial 
stiffness (Windham et al. 2010) and ED (Solini et al. 2012; Verma et al. 2003). 
However, its role in insulin resistance and obesity still remains uncertain in 
humans (Huang and Yang 2015; McTernan et al. 2002; Utzschneider et al. 
2005). 
The PAI-1 is a ~50 kDa glycoprotein that belongs to a class of serine protease 
inhibitors and acts as the primary physiological inhibitor of both the urokinase- 
and tissue-type plasminogen activators (Van Mourik et al. 1984). The protein is 
expressed in vascular endothelial cells, vascular smooth muscle cells, adipocytes, 
hepatocytes, platelets (PLTs), monocytes and macrophages, among others (Ha 
et al. 2009). Elevations in plasma PAI-1 levels can be observed in obesity 
(Landin et al. 1990; Solá et al. 2008) and may partially explain the increased 
risk of atherothrombotic events in overweight individuals (Wolk et al. 2003). 
Moreover, an autocrine role for adipocyte PAI-1 in promotion of adipocyte 
differentiation and lipid accumulation has been suggested (Correia and Haynes 
2006; Crandall et al. 2006). In addition to its prothrombotic effects (Eitzman et 
al. 2000), PAI-1 also seems to be associated with tissue fibrosis (Ghosh and 
Vaughan 2012) and atherosclerosis (Schneiderman et al. 1992), especially in 
patients with type 2 diabetes (Pandolfi et al. 2001; Sobel et al. 1998). Its pro-
duction by vascular endothelial cells is induced by a number of stimuli 
including interleukin-1 (Nachman et al. 1986) and TNF-α (Van Hinsbergh et al. 
1988). However, while PAI-1 seems to augment proliferation and to inhibit 
apoptosis of vascular smooth muscle cells (Chen et al. 2006; Rossignol et al. 
2006), it has also been reported to limit plaque growth and to prevent abnormal 
matrix remodeling (Luttun et al. 2002). Therefore, the true role of this adipokine 
in vascular remodeling remains controversial (Fay et al. 2007; Konstantinides et 
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al. 2002). In clinical studies, elevated circulating PAI-1 levels have been 
associated with both higher risk of CV events (Smith et al. 2005; Takazoe et al. 
2001) and mortality (Akkus et al. 2009). Yet, negative results have also been 
reported (Pineda et al. 2009; Wang et al. 2006). 
In the current thesis, serum adiponectin (Papers II and III), resistin (Papers 
I, II and IV) and PAI-1 (Paper I) levels were measured and their potential 
relationship with early biomarkers of renal damage and/or low molecular weight 
metabolites was assessed.  
 
 
2.3.3. Oxidized low-density lipoprotein 
An imbalance between oxidants and antioxidants in favour of the oxidants, 
potentially leading to damage, is termed ‘OxS’ (Sies 1997). Oxidative damage to 
nucleic acid bases, lipids, and proteins can, in turn, compromise cell health and 
viability (Dalle-Donne et al. 2006). It is therefore not surprising that elevated 
OxS has been suggested to be involved in the pathogenesis of numerous 
diseases (Alfadda and Sallam 2012). However, due to various shortcomings with 
the biomarkers and methods available to assess the OxS status, its patho-
physiological significance is often difficult to prove.  
Oxidized low-density lipoprotein (OxLDL) has been studied for more 
than three decades (Henriksen et al. 1981; Quinn et al. 1987; Steinbrecher et al. 
1984) and can be defined as follows: a particle derived from circulating LDL 
that may have peroxides or their degradation products (generated within the LDL 
molecule or elsewhere in the body) associated with the particle (Parthasarathy et 
al. 2010). The oxidation of LDL is a complex process during which both the 
protein and the lipids undergo oxidative changes and form complex products 
(Parthasarathy et al. 2010). A major role of OxLDL in promoting atherogenesis 
through foam cell formation and inflammatory responses is well-documented 
(Jones et al. 2000; Quinn et al. 1987; Van Tits et al. 2011; Ylä-Herttuala et al. 
1989). Higher circulating levels of this biomarker have been reported in various 
populations (Holvoet et al. 1998; Weinbrenner et al. 2006; Zagura et al. 2012). 
Moreover, elevated OxLDL levels seem to associate with hypertension (Froste-
gård et al. 2003), arterial stiffness (Zagura et al. 2012), carotid artery IMT 
(Kampus et al. 2007), early cardiac damage (Rietzschel et al. 2008), high waist 
circumference (Weinbrenner et al. 2006), type 2 diabetes (Njajou et al. 2009) and 
higher risk of future CV events (Meisinger et al. 2005; Shimada et al. 2004). 
In the current thesis, oxLDL levels were measured and their potential 
relationship with serum FBLN-1 (Paper I) and acylcarnitines (Paper III) in PAD 
patients, CAD patients and in clinically healthy subjects was evaluated.  
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2.4. Metabolic profiling of lipid metabolism in 
cardiovascular disease 
Alterations in lipid metabolism by itself and via interaction with a variety of 
other CV risk factors may promote the development of atherosclerotic disease. 
The levels of traditional lipid metabolism-related biomarkers (total cholesterol, 
LDL cholesterol, HDL cholesterol and triglycerides) have been used for decades 
in clinical practice to assess the risk for CVD. However, recent analytical 
advancements (e.g. metabolomics) may enable to further extend the current 
lipidomic signature for both CVD prognosis and risk stratification. 
 
 
2.4.1. Traditional lipid biomarkers of cardiovascular risk 
Cholesterol is an essential structural component of cellular membranes and lipid 
rafts (Rietveld and Simons 1998), influencing phospholipid bilayer fluidity and 
permeability (Cooper 1978). It is a precursor molecule for the synthesis of steroid 
hormones and bile salts and its biosynthesis is also related to the synthesis of 
vitamin D (Hanukoglu 1992). The blood levels of cholesterol are largely 
determined by its endogenous synthesis in the liver and, to a lesser extent, by 
dietary intake (Griffin and Lichtenstein 2013).  
Cholesterol is transported through the circulation by particles called blood 
lipoproteins. LDL particles are the major cholesterol carriers, and are responsible 
for transporting cholesterol to peripheral tissues. HDL particles, on the contrary, 
remove excess cholesterol from cells and from some other types of blood 
lipoproteins and deliver it back to the liver. Multiple RCTs have reported that 
reducing total cholesterol and LDL cholesterol can prevent CVD (Fulcher et al. 
2015; Pedersen et al. 1994; Reiner et al. 2011). Although statin therapy has been 
credited with various beneficial effects (Wang et al. 2008), a large-scale RCT 
published in 2015 provided the first evidence that LDL cholesterol lowering per 
se can explain the effect of statins on CV outcomes (Cannon et al. 2015). In 
addition, hypercholesterolemia has been positively associated with arterial stiff-
ness (Wilkinson et al. 2002; Wilkinson and Cockcroft 2007), although con-
flicting findings have also been reported (Cecelja and Chowienczyk 2009; Dart 
et al. 2004; Wilkinson and Cockcroft 2007). 
The role of HDL cholesterol in CVD is controversial. Observational data 
suggest that its concentration in blood is inversely associated with CV risk (Di 
Angelantonio et al. 2009; Castelli et al. 1986). Mendelian randomization studies 
(Voight et al. 2012) and interventional studies (Barter et al. 2007; Boden et al. 
2011), however, have not shown a causal link between elevated HDL cho-
lesterol and CV protection. Nonetheless, improving HDL functionality, rather 
than raising HDL cholesterol levels alone, might still prove to be an efficient 
way to improve CV outcomes in the future (Fazio and Linton 2010; Rohatgi et 
al. 2014). 
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High total triglyceride levels have long been recognized as a risk factor for 
CVD (Albrink and Man 1959; Brown et al. 1965). A triglyceride molecule 
consists of three fatty acids bound to a glycerol backbone and serves as an 
important storage of energy in the body. Recent genetic studies suggest that 
elevated concentrations of triglyceride-rich lipoproteins or their remnants are 
causally associated with CVD and all-cause mortality (Do et al. 2013; Jør-
gensen et al. 2013; Thomsen et al. 2014; Varbo et al. 2013). However, it still 
remains uncertain if lowering triglycerides reduces CVD in hypertriglyce-
ridemic patients. 
 
 
2.4.2. Metabolomics and novel lipid biomarkers of cardiovascular risk 
Systems biology in conjunction with omics techniques (genomics, transcrip-
tomics, proteomics and metabolomics) provide a holistic view of the molecular 
processes, ranging from a single cell to the whole organism. Metabolomics is 
focused on chemical processes involving low molecular weight (<1500 Da) 
metabolites (including amino acids, peptides, lipids, carbohydrates, nucleic 
acids, fatty acids) which reflect changes in the genome, transcriptome and 
proteome. Therefore, metabolomics represents the endpoint of the omics cascade 
and is closest to the actual phenotype. Two distinct approaches, targeted and 
untargeted metabolomics, can be followed to analyze a set of metabolites in 
biofluids or tissues. The aim of the targeted approach is to quantify only a pre-
selected set of known metabolites based on internal or external reference 
compounds. Untargeted metabolomics, on the other hand, refers to an analysis 
of all measurable metabolites in a biological sample. There are advantages and 
disadvantages to both strategies (Patti et al. 2012), and the choice of approach 
usually depends on the objectives of the experiment. 
As might be expected, metabolomic profiling of CVD has become a vibrant 
field of research. Altered lipid metabolism in atherosclerosis, in particular, has 
been the focus of a number of recent studies (Meikle et al. 2011; Rizza et al. 
2014; Shah et al. 2012; Stegemann et al. 2014). The field of lipidomics allows 
to survey a wide spectrum of lipid species in body fluids/tissues and provides 
new insights into the pathogenetic mechanisms of atherogenesis. Among these 
species, acylcarnitines, phosphatidylcholines (PCs) and lysophosphatidylcholines 
(lysoPCs) have received attention as potential novel independent lipid risk 
markers of CVD (Ganna et al. 2014; Shah et al. 2012; Sigruener et al. 2014). 
 
 
2.4.2.1. Acylcarnitines 
Conjugation to carnitine is required in order to transport activated long-chain 
fatty acids across the inner mitochondrial membrane. These carnitine esters are 
known as acylcarnitines. In the mitochondrial matrix, acylcarnitine reconjugates 
with a coenzyme-A (CoA) molecule after which reformed acyl-CoA undergoes 
β-oxidation to produce energy. However, when fatty acid release by adipose 
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tissue triglycerides exceeds the rate of β-oxidation, or when the oxidative 
metabolism of fatty acids in mitochondria is impaired (e.g. different inborn 
errors of mitochondrial β-oxidation (Vianey-Liaud et al. 1987; Wanders et al. 
1999)), the concentrations of different circulating acylcarnitines will be increased. 
An elevation in the levels of intramyocardiocellular long-chain acylcarnitines 
may also be induced by hypoxia (McHowat et al. 1993).  
Metabolomic profiles, composed of dicarboxylacylcarnitines, medium-chain 
acylcarnitines, and fatty acids, have been previously found to be independently 
predictive of future CV events and may improve risk discrimination beyond the 
degree possible using readily available clinical characteristics (Shah et al. 2012). 
A small study in elderly patients with a high rate of previous history of CAD also 
reported an independent association between medium- and long-chain acyl-
carnitines and the subsequent occurrence of CV events (Rizza et al. 2014). 
Furthermore, higher circulating levels of long-chain acylcarnitines are inde-
pendently predictive of the functional status and mortality in patients with 
chronic systolic heart failure (Ahmad et al. 2016). Importantly, these abnor-
malities seem to be modifiable with left ventricular assist device support in end-
stage heart failure patients (Ahmad et al. 2016).  
Taken together, these findings clearly indicate that medium- and long-chain 
acylcarnitines are associated with CV risk. However, whether the accumulation 
of these lipid species appears due to a metabolic shift toward myocardial fatty 
acid oxidation inhibition along with greater utilization of glucose (Neely and 
Morgan 1974), insulin resistance (Schooneman et al. 2013), defects in the 
‘carnitine shuttle’ leading to mitochondrial dysfunction (Ahmad et al. 2016), or 
other unknown mechanisms remains to be elucidated. 
In the current thesis, the serum levels of acylcarnitines were determined and 
their possible relationship with arterial stiffness, hemodynamics and inflam-
mation in patients with CAD and in clinically healthy subjects was evaluated 
(Paper III). 
 
 
2.4.2.2. Phosphatidylcholines 
The PCs are a class of glycerophospholipids which serve as structural compo-
nents in cellular membranes, blood lipoproteins, natural surfactants and bile, 
among others. A PC molecule can have numerous different combinations of fatty 
acids of varying lengths and saturation bound to the sn-1 (mostly saturated and 
monounsaturated fatty acids) and sn-2 (mostly polyunsaturated fatty acids) posi-
tions of the glycerol backbone, although those of 16-, 18- or 20-carbon chain 
length are the most common. For instance, a combination of myristic acid (C14:0) 
and linoleic acid (C18:2) at sn-1 and sn-2 positions, respectively, or palmitoleic 
acid (C16:1) at both sn-1 and sn-2 positions, can compose a PC aa C32:2 
molecule. Some fatty acids attached to the glycerol moiety (e.g. arachidonic acid, 
docosahexaenoic acid) serve as essential precursors to lipid-derived signaling 
molecules (Wymann and Schneiter 2008). Moreover, PCs are also reservoirs 
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and transporters of phosphate, glycerol and choline. The functional properties 
and oxidative susceptibility of individual PC molecules are largely determined by 
the diverse composition and distribution of saturated and unsaturated fatty acids 
on the glycerol backbone (Philippova et al. 2014). Alterations to PC molecular 
species composition can, in turn, result from an underlying (patho)physiological 
state (Delaš et al. 2008; Engelmann et al. 1992; McLeod and Sevanian 1997). 
A study in individuals hospitalized for coronary angiography showed that 
PC species containing long chain saturated and monounsaturated omega-9 (n-9) 
fatty acids were positively associated with mortality while long-chain polyun-
saturated fatty acids appeared to be associated with a protective effect in these 
patients (Sigruener et al. 2014). The authors considered it highly likely that the 
protective lipid species contain arachidonic acid (20:4 n-6) (Sigruener et al. 
2014); this view is supported by another study showing reduced CAD risk in 
subjects with an increased 20:4 (n-6) to 20:3 (n-6) ratio (i.e. increased delta-5 
desaturase activity) (Lu et al. 2012). 
In 2011, a positive relationship between gut-flora-dependent metabolism of 
dietary PC and atherosclerosis was discovered in mice (Wang et al. 2011). Gut 
bacteria metabolize the choline group of PC to trimethylamine which is further 
converted into pro-atherogenic trimethylamine-N-oxide in the liver. Subsequent 
large-scale human studies showed independent associations between elevated 
circulating trimethylamine-N-oxide and an increased risk of incident major 
adverse CV events (Tang et al. 2013; Wang et al. 2014) and thus further indicated 
a detrimental effect of trimethylamine-N-oxide on the CV system. 
In the present thesis, the serum concentrations of PCs were measured and 
their potential relationship with arterial stiffness, hemodynamics, ED and 
inflammation in CAD patients, PAD patients and clinically healthy subjects was 
examined (Papers III and IV) 
 
 
2.4.2.3. Lysophosphatidylcholines 
If PC molecule becomes partially hydrolized by phospholipase A2 or phos-
pholipase A1, one of the two fatty acids bound to the glycerol backbone is 
removed, and lysoPC is generated. The production of lysoPC can also result 
from lecithin-cholesterol acyltransferase activity (Subbaiah et al. 1980) or hepatic 
secretion (Sekas et al. 1985). These lipid species are major components of oxLDL 
and whereas some of these species seem to possess pro-atherogenic properties, 
others may have anti-atherogenic qualities (Aiyar et al. 2007; Hara et al. 1997; 
Schmitz and Ruebsaamen 2010). Like PCs, lysoPCs also serve as reservoirs and 
transporters of phosphate, glycerol and choline. Moreover, both lipid classes 
participate in cell signaling through multiple G protein-coupled receptors that 
regulate a wide range of cellular functions (Hara et al. 1997; Matsumoto et al. 
2006; Schmitz and Ruebsaamen 2010). 
Previous studies have suggested that lysoPCs are pro-inflammatory and 
pro-atherogenic metabolites that participate in monocyte adhesion (Weber et al. 
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1995), smooth muscle cell migration and proliferation (Kume and Gimbrone Jr 
1994) as well as in endothelium-dependent vasodilation impairment (Chen et al. 
1997). In contrast, recent large-scale prospective studies reported inverse asso-
ciations between circulating lysoPCs (e.g. 16:0, 18:0, 18:1, 18:2), CAD and 
total mortality (Ganna et al. 2014; Meikle et al. 2011; Sigruener et al. 2014; 
Stegemann et al. 2014). In patients with type 2 diabetes, lysoPC a C18:2 asso-
ciated negatively with both incident diabetes and impaired glucose tolerance 
(Wang-Sattler et al. 2012). Another study suggested that CVD development is 
preceded by reduced plasma levels of lysoPC a C16:0 and lysoPC a C20:4 and 
showed an inverse correlation between lysoPC a C16:0 and carotid IMT 
(Fernandez et al. 2013).  
The above-mentioned findings seem counterintuitive, since the production 
of lysoPCs depends largely on pro-atherogenic lipoprotein-associated phos-
pholipase A2. Furthermore, elevated lysoPC content in atherosclerotic plaques 
has also been reported (Stegemann et al. 2011). However, one can hypothesize 
that lower circulating lysoPC levels reflect their increased catabolism and more 
efficient removal from blood into tissues (Croset et al. 2000; Stegemann et al. 
2014), either in the form of oxLDL, or directly from albumin (Meikle et al. 
2011). Moreover, lower activity of lecithin-cholesterol acyltransferase may also 
partially explain reduced circulating lysoPC levels in atherosclerotic patients 
(Duivenvoorden et al. 2011; Rasmiena et al. 2013). Thus, the pro- or antiathero-
genicity of a lysoPC molecule seems to be dependent on the physical properties 
of its fatty acid residue (e.g. 16:0, 18:1, 20:4). 
In the current thesis, the serum levels of various lysoPCs were determined 
and their possible relationship with arterial stiffness, hemodynamics, ED and 
inflammation in CAD patients, PAD patients and in clinically healthy subjects 
was assessed (Papers III and IV). 
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3. AIMS OF THE THESIS 
The general aim of the present thesis was to determine the metabolomic profile 
of arterial stiffness and the role of early biomarkers of renal damage in patients 
with atherosclerosis and in clinically healthy subjects. 
 
 
Specific aims 
 
1.  To measure the serum levels of fibulin-1 (FBLN-1) and their association 
with arterial stiffness and inflammation in non-diabetic coronary artery 
disease patients, peripheral arterial disease patients and in clinically healthy 
controls.  
2.  To determine the serum levels of neutrophil gelatinase-associated lipocalin 
(NGAL) and cystatin C (CysC) and the urinary concentrations of liver-type 
fatty acid-binding protein (L-FABP) and kidney injury molecule-1 (KIM-1), 
as well as to evaluate their association with arterial stiffness and inflam-
mation in coronary artery disease patients without moderate to severe chronic 
kidney disease (estimated glomerular filtration rate ≥ 60 mL/min/1.73 m2) 
and in clinically healthy subjects. 
3.  To investigate the relationship of aortic stiffness, hemodynamics and inflam-
mation with serum acylcarnitines in patients with coronary artery disease and 
in clinically healthy controls. 
4.  To study serum phosphatidylcholine and lysophosphatidylcholine species in 
relation to arterial stiffness, hemodynamics and endothelial dysfunction in 
coronary artery disease patients, peripheral arterial disease patients and in 
clinically healthy subjects. 
5.  To observe and analyze similarities and differences in arterial function and 
in metabolomic and inflammatory profiles between patients with coronary 
artery disease and patients with peripheral arterial disease. 
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4. SUBJECTS AND METHODS 
4.1. Study population 
4.1.1. Patients with symptomatic coronary artery disease and  
patients with symptomatic peripheral arterial disease 
A total of 90 male patients, including 52 subjects with stable CAD (n=38, n=52, 
n=52, n=52 in Papers I–IV, respectively) and 38 subjects with symptomatic 
PAD (n=38 and n=32 in Papers I and IV, respectively), were recruited from the 
Department of Cardiology and from the Department of Vascular Surgery, Tartu 
University Hospital, Estonia. The diagnoses of CAD and PAD were established 
based on significant stenoses (≥50% diameter reduction) or occlusions of 
arteries confirmed by coronary angiography and digital subtraction angiography 
of the abdominal aorta and lower extremities, respectively. The PAD patients 
fell into four stages according to the Fontaine: stage II = intermittent clau-
dication (n=24 and n=22 in Papers I and IV, respectively); stage III = leg pain at 
rest (n=6 and n=3 in Papers I and IV, respectively); stage IV = focal tissue 
necrosis or gangrene (n=8 and n=7 in Papers I and IV, respectively). The 
exclusion criteria for both patient groups were any comorbid acute or chronic 
inflammatory disease, diabetes mellitus (fasting serum glucose level >7 mmol/L), 
MI, cerebrovascular events or revascularization operation during the preceding 
6 months, unstable angina, cardiac arrhythmias, clinically significant heart 
failure or valvular disease, reduced kidney function (eGFR <60 ml/min/1.73 m2), 
presence of cancer or endocrine pathology. In Papers II and IV, 6 (16%) PAD 
patients with CAD as the comorbidity were included in analysis. CAD patients 
with symptomatic PAD were not recruited. 
 
 
4.1.2. Clinically healthy subjects 
In total, 41 age- and gender-matched clinically healthy controls (n=30, n=41, 
n=40 and n=40 in Papers I–IV, respectively) were identified through local 
family physicians in the same geographical area. The following exclusion criteria 
were set: any comorbid acute or chronic inflammatory disease, CAD, cerebral 
or peripheral atherosclerotic disease, diabetes mellitus, cardiac arrhythmias, 
clinically significant heart failure or valvular disease, reduced kidney function 
(eGFR<60 ml/min/1.73 m2), presence of cancer, infectious disease or endocrine 
pathology. None of the subjects was on regular medication. 
 
 
4.2. Study design and protocol 
All subjects completed a lifestyle and medical history questionnaire. Venous 
blood samples were drawn from each subject (Papers I–IV) and spot morning 
urine specimens were collected from 45 CAD patients and 37 controls (Paper 
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II). All samples were obtained between 8am and 11am after an overnight fast and 
abstinence from tobacco, alcohol and caffeine-containing beverages. Height and 
weight were assessed and body mass index (BMI) was calculated. The subjects 
were studied after 10 minutes of rest in a supine position in a quiet, temperature-
controlled room. Thereafter, brachial BP, cf-PWV and cr-PWV (Paper I) were 
assessed and PWA was made. All hemodynamic measurements were taken in 
duplicate and averaged. Each subject gave his written informed consent, and the 
study protocol was approved by the Ethics Committee of the University of Tartu. 
 
 
4.3. Methods 
4.3.1. Biochemical analysis of blood and urine 
Peripheral venous blood samples were collected in serum separator tubes (BD 
SST™ II Advance) for biochemical analysis (Papers I–IV). The serum levels of 
glucose, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, 
white blood cell (WBC) count, PLT count, hsCRP, CysC, urea, creatinine 
(eGFR was calculated by the Chronic Kidney Disease Epidemiology 
Collaboration equation (Levey et al. 2009)), and urinary creatinine were 
measured in the local clinical laboratory with automated analyzers using 
standard laboratory methods. 
Other blood samples were centrifuged within 30 minutes of collection and 
the serum was pipetted into Eppendorf tubes. The tubes were stored at −70 °C 
until assayed. The serum levels of IL-6, ferritin, PAI-1, resistin and insulin were 
determined using The Evidence Investigator (Metabolic Syndrome Array-1, 
Randox Laboratories, Crumlin, UK). Serum FBLN-1, NGAL, MPO, oxLDL and 
adiponectin levels were measured using an enzyme-linked immunosorbent assay 
(ELISA) (Human Fibulin-1 Kit, Cusabio Biotech Co., Ltd; Human Lipocalin-2/ 
NGAL immunoassay, R&D Systems Europe, Abingdon, UK; Myeloperoxidase 
enzyme immunoassay test kit, BIOCHECK, Inc. Foster City, CA; Merdcodia 
Oxidized LDL ELISA, Uppsala, Sweden; Human Total Adiponectin/Acrp30 
immunoassay, R&D Systems Europe, Abingdon, UK, respectively).  
Urine samples were collected in sterile plastic collection cups, aliquoted into 
Eppendorf tubes and kept frozen at −70 °C until analysis. The levels of urinary 
L-FABP and KIM-1 were measured using ELISA (Human Liver Fatty Acid 
Binding Protein-1 ELISA kit, BlueGene Biotech, Shanghai, China; HAVCR1 
(Human), KIM-1, Abnova GmbH, Heidelberg, Germany, respectively). 
 
 
4.3.2. Targeted serum metabolite profiling 
Peripheral venous blood samples were collected in plain tubes (Plain BD 
Vacutainer® Tubes) for metabolomic analysis (Papers III and IV). All samples 
were centrifuged within 60 minutes of collection and the supernatant was 
transferred into Eppendorf tubes. The tubes were frozen at −70 °C until assayed. 
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The serum levels of metabolites were determined with the AbsoluteIDQ™ p180 
kit (BIOCRATES Life Sciences AG, Innsbruck, Austria) using the flow 
injection analysis tandem mass spectrometry as well as liquid chromatography 
techniques. All measurements were performed as described in the manu-
facturer’s manual UM-P180. The AbsoluteIDQ™ p180 kit allows simultaneous 
quantification of 186 metabolites (acylcarnitines (Cx:y), amino acids and biogenic 
amines, hexose, sphingolipids (SM x:y or SM (OH) x:y), glycerophospholipids 
(lysoPCs (lysoPC a x:y) and PCs (PC aa x:y and PC ae x:y)) from 10 µL of serum 
(Table 1). Lipid side-chain composition is abbreviated as Cx:y, where x denotes 
the number of carbons in the side chain and y denotes the number of double 
bonds. Glycerophospholipids are differentiated further according to the 
presence of ester and ether bonds in the glycerol moiety. Double letters 
(aa = diacyl, ae = acyl-alkyl) indicate that two glycerol positions are bound to a 
fatty acid residue, while a single letter (a = acyl or e = alkyl) indicates a bond with 
only one fatty acid residue. Identification and quantification of the metabolites 
was achieved using multiple reaction monitoring along with internal standards. 
The concentrations of all metabolites were automatically calculated in μM by 
the MetIDQ™ software (BIOCRATES Life Sciences AG). Metabolites below 
the limit of detection (n=35 and n=7 in Papers III and IV, respectively), 
determined experimentally by BIOCRATES, were excluded from further 
analysis. The assay procedures of the AbsoluteIDQ™ p180 kit have been 
described in detail previously (Nkuipou-Kenfack et al. 2014). 
Table 1. Low molecular weight metabolites that were quantified using the AbsoluteIDQ® 
p180 kit (http://www.biocrates.com/images/ListofMetabolites_p180.pdf) in our study. 
ACYLCARNITINES 
C0  Carnitine  C10:1  Decenoylcarnitine  
C2  Acetylcarnitine  C10:2  Decadienylcarnitine  
C3  Propionylcarnitine  C12  Dodecanoylcarnitine  
C3:1  Propenoylcarnitine  C12:1  Dodecenoylcarnitine  
C3-OH  Hydroxypropionylcarnitine  C12-DC  Dodecanedioylcarnitine  
C4  Butyrylcarnitine  C14  Tetradecanoylcarnitine  
C4:1  Butenylcarnitine  C14:1  Tetradecenoylcarnitine  
C4-OH (C3-DC)  Hydroxybutyrylcarnitine  C14:1-OH  Hydroxytetradecenoylcarnitine  
C5  Valerylcarnitine  C14:2  Tetradecadienylcarnitine  
C5:1  Tiglylcarnitine  C14:2-OH  Hydroxytetradecadienylcarnitine  
C5:1-DC  Glutaconylcarnitine  C16  Hexadecanoylcarnitine  
C5-DC (C6-OH)  Glutarylcarnitine 
(Hydroxyhexanoylcarnitine)  
C16:1  Hexadecenoylcarnitine  
C5-M-DC  Methylglutarylcarnitine  C16:1-OH  Hydroxyhexadecenoylcarnitine  
C5-OH (C3-DC-M)  Hydroxyvalerylcarnitine 
(Methylmalonylcarnitine)  
C16:2  Hexadecadienylcarnitine  
C6 (C4:1-DC)  Hexanoylcarnitine 
(Fumarylcarnitine)  
C16:2-OH  Hydroxyhexadecadienylcarnitine  
C6:1  Hexenoylcarnitine  C16-OH  Hydroxyhexadecanoylcarnitine  
C7-DC  Pimelylcarnitine  C18  Octadecanoylcarnitine  
C8  Octanoylcarnitine  C18:1  Octadecenoylcarnitine  
C9  Nonaylcarnitine  C18:1-OH  Hydroxyoctadecenoylcarnitine  
C10  Decanoylcarnitine  C18:2  Octadecadienylcarnitine  
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Table 1. Continued 
AMINO ACIDS AND BIOGENIC AMINES 
Ala  Alanine  Ac-Orn  Acetylornithine  
Arg  Arginine  ADMA  Asymmetric dimethylarginine  
Asn  Asparagine  SDMA  Symmetric dimethylarginine  
Asp  Aspartate  alpha-AAA  alpha-Aminoadipic acid  
Cit  Citrulline  Carnosine  Carnosine  
Gln  Glutamine  Creatinine  Creatinine  
Glu  Glutamate  Histamine  Histamine  
Gly  Glycine  Kynurenine  Kynurenine  
His  Histidine  Met-SO  Methioninesulfoxide  
Ile  Isoleucine  Nitro-Tyr Nitrotyrosine  
Leu  Leucine  cis-OH-Pro  cis-4-Hydroxyproline  
Lys  Lysine  trans-OH-Pro  trans-4-Hydroxyproline  
Met  Methionine  PEA  Phenylethylamine  
Orn  Ornithine  Putrescine  Putrescine  
Phe  Phenylalanine  Sarcosine  Sarcosine  
Pro  Proline  Serotonin  Serotonin  
Ser  Serine  Spermidine  Spermidine  
Thr  Threonine  Spermine  Spermine  
Trp  Tryptophan  Taurine  Taurine  
Tyr  Tyrosine  Dopamine  Dopamine  
Val  Valine  DOPA  DOPA  
MONOSACCHARIDES                        GLYCEROPHOSPHOLIPIDS 
Sum of Hexoses lysoPC a C16:0  PC aa C36:3  PC ae C34:2  
lysoPC a C16:1  PC aa C36:4  PC ae C34:3  
SPHINGOLIPIDS lysoPC a C17:0  PC aa C36:5  PC ae C36:0  
lysoPC a C18:0  PC aa C36:6  PC ae C36:1  
SM (OH) C14:1  lysoPC a C18:1  PC aa C38:0  PC ae C36:2  
SM C16:0  lysoPC a C18:2  PC aa C38:1 PC ae C38:3  
SM C16:1  lysoPC a C20:3  PC aa C38:3  PC ae C38:4  
SM (OH) C16:1  lysoPC a C20:4  PC aa C38:4  PC ae C38:5  
SM C18:0  lysoPC a C24:0  PC aa C38:5  PC ae C38:6  
SM C18:1  lysoPC a C26:0  PC aa C38:6  PC ae C40:1  
SM C20:2  lysoPC a C26:1  PC aa C40:1  PC ae C40:2  
SM C22:3 1) 2)  lysoPC a C28:0  PC aa C42:1  PC ae C40:3  
SM (OH) C22:1  lysoPC a C28:1  PC aa C42:2  PC aa C40:4  
SM (OH) C22:2  PC aa C24:0  PC aa C42:4  PC ae C40:5  
SM C24:0  PC aa C26:0  PC aa C42:5  PC ae C40:6  
SM C24:1  PC aa C28:1  PC aa C42:6  PC ae C42:0  
SM (OH) C24:1  PC aa C30:0  PC ae C30:0  PC ae C42:1  
SM C26:0  PC aa C34:2  PC ae C30:1  PC ae C42:2  
SM C26:1  PC aa C34:3  PC ae C30:2  PC ae C42:3  
PC aa C34:4  PC ae C32:1  PC ae C42:4  
PC aa C36:0  PC ae C32:2  PC ae C42:5  
PC aa C36:1  PC ae C34:0  PC ae C44:3  
PC aa C36:2  PC ae C34:1  
Abbreviations: a, acyl; aa, diacyl; ae, acyl-alkyl; lysoPC, lysophosphatidylcholine; PC, phosphatidylcholine; 
SM, sphingomyelin. 
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4.3.3. Peripheral blood pressure measurement 
Brachial BP was measured using an automatic oscillometric BP monitor 
(OMRON M4-I; Omron Healthcare Europe, Hoofdorp, the Netherlands) fol-
lowing 10 minutes of supine rest (Papers I–IV). The MAP was calculated from 
integration of the radial pressure waveform using the Sphygmocor software 
(SCOR® Px, 7.0; AtCor Medical, Sydney, Australia). The difference between 
peripheral systolic BP (PSBP) and peripheral diastolic BP (PDBP) was ex-
pressed as PPP. The PPP/CPP (Paper I) was defined as the percentage ratio of 
PPP to CPP (the difference between CSBP and CDBP). All BP measurements 
were taken in duplicate and the mean values were used in subsequent analyses. 
 
 
4.3.4. Assessment of arterial stiffness and central hemodynamics 
4.3.4.1. Pulse wave analysis 
Central hemodynamic parameters, namely CSBP, CDBP, CPP, travel time of 
the reflected wave and central AIx were evaluated non-invasively by PWA 
(Papers I–IV), using the SphygmoCor device (version 7.1, AtCor Medical, 
Sydney, Australia). At least 15 sequential high-quality radial artery pressure 
waveforms were recorded at the patient’s left wrist using a high-fidelity micro-
manometer (SPT-301B; Millar Instruments, USA). Thereafter, a validated 
generalized transfer function for calculation of the central aortic pressure wave-
form was employed (Adji et al. 2011; Pauca et al. 2001). The AIx was defined 
as the difference between the second and first systolic peaks of the central aortic 
wave, expressed as a percentage of CPP (Laurent et al. 2006). It was corrected 
for a heart rate of 75 beats per minute (AIx@75) by a Sphygmocor built-in 
algorithm. 
 
 
4.3.4.2. Pulse wave velocity 
The PWV was obtained by sequential recordings of the carotid and femoral (cf-
PWV in Papers I–IV) or radial (cr-PWV in Paper I) pulse waveforms 
(SphygmoCor Px, version 7.1, AtCor Medical, Australia) using an arterial 
tonometer (SPT-301B, Millar Instruments, USA). The R wave of the ECG signal 
serves as the reference in determining the time it takes a pulse wave to travel 
between two measuring sites. The PWV (m/s) was calculated as a ratio between 
traveled distance and transit time (PWV=distance/time) (Van Bortel et al. 2012). 
The tape measure distance from the suprasternal notch over the umbilicus to the 
femoral artery minus carotid arterial length was used for the calculation of cf-
PWV; to calculate cr-PWV, the distance from the suprasternal notch to the 
radial artery minus carotid arterial length was required. Recordings where heart 
rate varied more than 5 beats per minute were excluded. All PWV measure-
ments were taken in duplicate and the mean values were used in subsequent 
analysis. 
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4.3.5. Measurement of angiographic score 
In patients with PAD, digital subtraction angiography (Axiom Artis; Siemens 
Medical Solutions, Forchheim, Germany) of the aorta and lower extremity 
arteries was performed using a femoral approach at the Department of Radiology, 
Tartu University Hospital, Estonia. The angiographic score for this vascular 
region (Nylaende et al. 2006) was determined by an experienced radiologist, 
who was blinded to all other data. For the 21-segment model, the following 
arterial segments were evaluated: abdominal aorta, common iliac artery, external 
iliac artery, common femoral artery, profunda femoris artery, superficial femoral 
artery, popliteal artery, tibio-peroneal trunk, anterior tibial artery, posterior 
tibial artery and peroneal artery. Severity of luminar narrowing was graded as 
follows: 0 = normal; 1 = stenosis <50%; 2 = stenosis >50%; 3 = occlusion 
(Nylaende et al. 2006). A score was assigned only to the area with the most 
severe stenosis in each segment. These scores were then summed to obtain the 
overall angiographic score (maximum 63) (Paper IV).  
 
 
4.3.6. Statistical analysis 
All statistical analyses were performed with the Statistical Package for the 
Social Sciences software for Windows, version 22.0 (Chicago, IL, USA). 
Continuous variables are expressed as mean±standard deviation or as median 
and interquartile ranges. Categorical variables are expressed in percentages. The 
normality of the distribution of continuous variables was assessed using the 
Shapiro-Wilk test (Papers I–IV), and the skewed distributions were normalized 
by logarithmic transformation.  
Comparisons between the two independent groups were performed using 
two-tailed Student’s t-test for normally distributed data and the Mann-Whitney 
U test for non-normal data. One-way analysis of variance was employed for 
comparing the mean values of normally distributed variables among the three 
unpaired groups, and post hoc analysis was performed by the Scheffé test 
(Scheffé 1959) to check for intergroup differences (Papers I and IV). A Kruskal-
Wallis test was conducted to determine differences between the median values 
of non-normally distributed variables among the three unpaired groups and 
pairwise comparisons were performed using Dunn's procedure (Dunn 1964) 
with a Bonferroni correction for multiple comparisons (Papers I and IV). For 
the dichotomous measures, Fisher’s exact test or chi-square test was employed 
to compare two groups for each variable (Papers II and III), and the Fisher-
Freeman-Halton test was conducted when the three groups were compared 
(Papers I and IV). 
Pearson’s correlation coefficient and Spearman's rank correlation coefficient 
were used to measure the strength of the relationship between normally and 
non-normally distributed continuous variables, respectively. Multiple regression 
analysis was applied to investigate the independent determinants of AIx@75 
(Paper I), FBLN-1 (Paper I), cf-PWV (Papers II–IV), heart rate (Paper IV), 
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ADMA (Paper IV) and ADMA/Arg (Paper IV). Explanatory power of the 
regression models was estimated with adjusted R2 values. 
Analysis of covariance was used as follows: 1) to adjust cf-PWV (Papers I–
IV) and cr-PWV (Paper I) for MAP, 2) to adjust low molecular weight 
metabolites for BMI and statin use (Paper III), and 4) to adjust low molecular 
weight metabolites for BMI, statin use and smoking status (Paper IV).  
Principal component analysis (PCA) was employed to reduce the large 
number of correlated metabolites to fewer uncorrelated factors (Paper III). To 
identify interpretable factors, Varimax rotation was carried out; only the factors 
that explained at least 5% of total variance were retained. Also, only the meta-
bolites with absolute factor loadings ≥0.60 were reported as the components of a 
given factor in order to avoid false discoveries. Thereafter, for each subject, 
factor scores (weighted sum of the standardized metabolites within that factor, 
weighted on the factor loading for each individual metabolite) were calculated 
and included in the subsequent analyses. 
Statistical significance was defined as p<0.05 (Papers I–IV). To account for 
multiple testing the Benjamini-Hochberg procedure (Benjamini and Hochberg 
1995) was used to control false discovery rate at the level of 0.05 (Papers III–
IV). 
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5. RESULTS 
5.1. Relationships between serum fibulin-1,  
arterial stiffness and inflammation in patients  
with atherosclerosis and in healthy subjects (Paper I) 
Characteristics of the study population 
The baseline characteristics of the study groups are presented in Table 2. There 
were no significant differences in mean age, PDBP, CDBP, total and LDL 
cholesterol, oxLDL, PAI-1 or resistin levels between the investigated groups. 
The patients with PAD differed significantly from both the CAD and control 
subjects with respect to height, PSBP, CSBP, PPP/CPP, WBC count, HDL 
cholesterol, hsCRP, AIx@75 and current smoking status. Differences in MAP, 
heart rate, cf-PWV, PLT count, triglycerides and FBLN-1 levels only emerged 
from comparison to the controls. The CAD patients had significantly higher 
BMI and glucose levels than the PAD patients and higher cr-PWV and WBC 
count than the controls. Medication use among the three study groups is 
presented in Table 3. 
 
Association between arterial stiffness and biochemical markers 
In univariate analysis, FBLN-1 correlated positively with AIx@75 for the PAD 
patients (rho=0.37, p=0.021; Figure 2) (this relationship retained significance 
even after excluding outliers, r=0.47, p=0.005), but not for the CAD patients 
(rho=–0.02, p=0.91) or for the control group (r=0.01, p=0.95). In multivariate 
analysis with AIx@75 as the dependent variable, FBLN-1, MAP and height 
were significant independent variables in the PAD group (R2=0.45; p<0.001; 
Table 4). There was no correlation between serum FBLN-1 and cf-PWV in any 
of the studied groups (data not shown).  
In univariate analysis, FBLN-1 was correlated with resistin (rho=0.40; 
p=0.013), WBC count (rho=0.39; p=0.018) and PLT count (rho=0.38; p=0.019) 
for the PAD group, while in multivariate analysis with FBLN-1 as the 
dependent variable, resistin and AIx@75, remained significant determinants for 
these patients (R2=0.31, p=0.002; Table 5). In the CAD group, WBC count 
(rho=0.36, p=0.035) and height (rho=–0.41, p=0.012) correlated univariately 
with FBLN-1 and remained significant in multivariate analysis (R2=0.33, 
p=0.002; Table 5), while for the control subjects, only PAI-1 was found to 
correlate with FBLN-1 (r=0.39; p=0.048). However, this difference did not 
reach statistical significance in multivariate analysis (data not shown). 
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Table 2. Baseline characteristics of the study groups. 
Variable PAD patients 
(n=38) 
CAD patients 
(n=38) 
Controls 
(n=30) 
p-value 
Age (years)  62.4 ± 9.0  64.0 ± 9.5  61.1 ± 6.4 0.36 
BMI (kg/m2)  25.5 ± 3.3b  27.5 ± 3.2  26.0 ± 3.3 0.02 
Height (cm)  172.0 ± 5.8a,b  175.8 ± 6.6  179.2 ± 6.5 <0.001 
Peripheral SBP (mmHg)  144 ± 18a,b  135 ± 15  127.0 ± 13 <0.001 
Peripheral DBP (mmHg)  81 ± 9  78 ± 8  77 ± 7 0.20 
Central SBP (mmHg)  135 ± 17a,b  124 ± 13  118 ± 13 0.004 
Central DBP (mmHg)  81 ± 10  79 ± 7  78 ± 7 0.25 
MAP (mmHg)  103 ± 12a  97 ± 9  95 ± 10 0.004 
Heart rate (bpm)  64.6 ± 11.3a  61.4 ± 7.8  57.6 ± 7.3 0.008 
PPP/CPP  1.19 ± 0.9a,b  1.28 ± 0.1  1.28 ± 0.1 0.001 
WBC count (x109/L)  7.8 ± 1.9a,b  6.3 ± 1.6a  4.9 ± 0.6 <0.001 
PLT count (x109/L)  244 ± 59a  219 ± 48  213 ± 31 0.03 
Total cholesterol (mmol/L)  5.4 ± 1.2  5.2 ± 1.1  5.5 ± 1.0 0.41 
HDL cholesterol (mmol/L) 1.1 (1.0–1.4)a,b 1.5 (1.1–1.7) 1.5 (1.3–1.8) <0.001 
LDL cholesterol (mmol/L)  3.6 ± 1.1  3.4 ± 1.1  3.6 ± 0.9 0.54 
Triglycerides (mmol/L) 1.6 (0.9–2.2)a 1.2 (0.8–1.7) 0.9 (0.7–1.4) 0.01 
Glucose (mmol/L)  5.4 ± 0.8b  5.8 ± 0.6  5.8 ± 0.5 0.02 
eGFR (ml/min/1,73 m2)  91.1 ± 18.4  82.8 ± 14.4  83.4 ± 11.6 0.04 
hsCRP (mg/L) 4.4 (1.1–7.6)a,b 1.3 (0.8–2.6) 1.1 (0.7–2.0) <0.001 
oxLDL (U/L) 67.5 (53.4–85.6) 61.0 (50.3–81.8) 66.3 (53.5–84.4) 0.63 
PAI-1 (ng/ml)  28.0 ± 9.3  26.4 ± 8.7  27.3 ± 6.6 0.73 
Resistin (ng/ml) 3.5 (2.8–4.5) 3.7 (2.8–4.9) 2.8 (2.4–3.4) 0.25 
Fibulin-1 (μg/ml) 9.4 (4.9–17.8)a 7.1 (4.8–11.8) 5.6 (4.1–8.4) 0.005 
AIx@75 (%)  29.4 ± 7.2a,b  19.2 ± 7.2  15.4 ± 7.1 <0.001 
cf-PWV (m/s)c  9.8 ± 2.2a  9.5 ± 2.2  8.3 ± 2.2 0.023 
cr-PWV (m/s)c  9.3 ± 1.2  9.5 ± 1.1a  8.7 ± 1.2 0.024 
Current smoking, n (%) 28 (72)a,b 8 (21) 3 (10) <0.001 
a = <0.05 vs control group 
b = <0.05 vs CAD group 
c = cf-PWV and cr-PWV have been adjusted for MAP. 
 
The values are represented as means (± standard deviation), medians (inter-
quartile range), or prevalence (%). AIx@75, augmentation index adjusted to a 
heart rate of 75 beats per minute; BMI, body mass index; CAD, coronary artery 
disease; cf-PWV, carotid–femoral pulse wave velocity; cr-PWV, carotid–radial 
pulse wave velocity; DBP, diastolic blood pressure; eGFR, estimated glomerular 
filtration rate; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive 
protein; LDL, low-density lipoprotein; MAP, mean arterial pressure; PAD, peri-
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pheral arterial disease; PAI-1, plasminogen activator inhibitor-1; PLT, platelet; 
PPP/CPP, pulse pressure amplification; SBP, systolic blood pressure; WBC, 
white blood cell. 
 
Table 3. Medication use among the three study groups. 
 PAD patients 
(n=38) 
CAD patients
(n=38) 
Controls 
(n=30) 
p-value 
Medication, n (%) 
ACE inhibitors  9  (23)a  13  (34)a 0 (0) <0.001 
ARBs  6  (15)  6  (16) 0 (0) 0.04 
Calcium channel blockers  6  (15)b  14  (37)a 0 (0) <0.001 
Beta blockers  10  (26)a,b  27  (71)a 0 (0) <0.001 
Diuretics  3 (8)  4  (11) 0 (0) 0.20 
Pentoxyfylline  13  (33)a,b  0  (0) 0 (0) <0.001 
Naftidrofuryl  8  (21)a,b  0  (0) 0 (0) <0.001 
Antiplatelets  13  (33)a,b  26  (68)a 0 (0) <0.001 
Statins  7  (18)a,b  20  (53)a 0 (0) <0.001 
a = <0.05 vs control group 
b = <0.05 vs CAD group 
 
The values are represented as prevalence (%). ACE, angiotensin-converting 
enzyme; ARB, angiotensin receptor blocker. 
 
 
Figure 2. Scatterplot showing correlation between heart rate-corrected augmentation 
index (AIx@75) and serum fibulin-1 for the peripheral arterial disease patients 
(rho=0.37, p=0.021). 
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Table 4. Multiple regression model for PAD group with AIx@75 as the dependent 
variable. 
Variable Regression coefficient Standard error p-value 
FBLN-1 0.477 0.117 <0.001 
MAP 0.222 0.069 0.003 
Height –0.298 0.140 0.041 
R2=0.454, p<0.001. AIx@75, augmentation index adjusted to a heart rate of 75 beats per minute; 
FBLN-1, fibulin-1; MAP, mean arterial pressure; PAD, peripheral arterial disease. 
 
 
Table 5. Multiple regression model for PAD and CAD patients with FBLN-1 as the 
dependent variable. 
Variable Regression coefficient Standard error p-value 
PAD patientsa
AIx@75 0.495 0.160 0.004 
Resistin 1.523 0.719 0.042 
Antihypertensive treatment –2.710 2.046 0.195 
CAD patientsb
WBC count 0.875 0.328 0.013 
Height –0.210 0.081 0.015 
Statin treatment –1.933 1.095 0.089 
a R2=0.314, p=0.002; b R2=0.332, p=0.002. AIx@75, augmentation index adjusted to a heart rate 
of 75 beats per minute; CAD, coronary artery disease; FBLN-1, fibulin-1; PAD, peripheral 
arterial disease; WBC, white blood cell.  
 
 
5.2. Early biomarkers of renal damage in relation to 
arterial stiffness and inflammation in coronary artery 
disease patients and in healthy subjects (Paper II) 
Characteristics of the study population 
The clinical and laboratory characteristics of the CAD cases and the controls are 
presented in Table 6. There were no significant differences between the groups 
with respect to mean age, PDBP, CSBP, CDBP, MAP, current smoking status, 
total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, 
hsCRP or ferritin levels. The two groups differed in BMI, height, PSBP, heart 
rate, cf-PWV, AIx@75, medication use, as well as in WBC count and serum 
MPO, IL-6, adiponectin and resistin levels. There were no significant differences 
in eGFR, serum creatinine, urea, CysC, NGAL, urinary L-FABP or KIM-1 
levels between the patients and the controls (Table 7). 
 
44 
Association between arterial stiffness and markers of renal function and 
tubular damage 
In a univariate analysis for the predefined variables, log L-FABP (r=0.44, 
p=0.002; Figure 3), CysC (r=0.52, p<0.001), eGFR (rho=–0.36, p=0.012) and 
creatinine (r=0.33, p=0.021) correlated positively with cf-PWV for the CAD 
group but not for the controls (data not shown). Also, log KIM-1 showed a 
borderline significant relationship (r=0.29, p=0.062) with aortic stiffness for the 
patients. In multivariate analysis with cf-PWV as the dependent variable, L-FABP 
and KIM-1 were the only renal markers that remained significant after adjust-
ment for potential confounders (mean age, BMI, MAP, NGAL, eGFR, hsCRP, 
IL-6, glucose, cholesterol, triglycerides, smoking status, antihypertensive 
therapy and statin use) (R2=0.58; p<0.001; Table 8). In the post hoc subgroup 
analyses based on eGFR levels, L-FABP (r=0.6, p=0.002) showed a strong and 
CysC (r=0.4, p=0.043) a moderate correlation with cf-PWV for the subgroup of 
CAD patients with eGFR between 60 and 89 mL/min/1.73 m2.  
Serum NGAL was not correlated with cf-PWV or any other measure of 
arterial stiffness for either CAD patients or controls (data not shown).  
In the control group, a significant inverse correlation was found between 
serum resistin levels and log L-FABP (r=–0.34, p=0.045). Serum NGAL levels 
correlated with WBC count (rho=0.29, p=0.038; r=0.35, p=0.029) and resistin 
(rho=0.60, p<0.001; r=0.57, p<0.001) for the CAD and control groups, 
respectively, and with serum creatinine (rho=0.31, p=0.030) only for the CAD 
group. Urinary log KIM-1 was linearly correlated with serum creatinine (r=0.33, 
p=0.019), adiponectin (r=0.31, p=0.028) and log ferritin (r=–0.32, p=0.022) 
levels for the CAD group while no such correlations were found for the controls. 
 
Table 6. Baseline characteristics of the study groups. 
Variable CAD patients 
(n=52) 
Controls 
(n=41) 
p-value 
Age (years)  63.2 ± 9.2  60.1 ± 7.2 0.075 
Body mass index (kg/m2)  27.9 ± 3.5  26.0 ± 3.4 0.012 
Height (cm)  176.2 ± 6.4  179.3 ± 6.5 0.025 
Peripheral SBP (mmHg)  135.0 ± 14.5  128.4 ± 13.2 0.027 
Peripheral DBP (mmHg)  78.5 ± 8.0  77.9 ± 7.3 0.706 
Central SBP (mmHg)  122.7 ± 11.1  119.8 ± 15.1 0.303 
Central DBP (mmHg)  79.7 ± 7.6  78.4 ± 6.7 0.378 
MAP (mmHg) 96.0 (91.6–101.4) 92.5 (89.5–99.5) 0.103 
Heart rate (bpm)  62.8 ± 8.3  57.8 ± 7.1 0.003 
WBC count (x109/L) 6.4 (5.2–7.9) 5.1 (4.7–5.8) 0.001 
Total cholesterol (mmol/L)  5.1 ± 1.0  5.5 ± 0.9 0.080 
HDL cholesterol (mmol/L)  1.5 ± 0.4  1.6 ± 0.4 0.153 
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Table 6. Continued 
Variable CAD patients 
(n=52) 
Controls 
(n=41) 
p-value 
LDL cholesterol (mmol/L) 3.2 (2.8–4.1) 3.7 (3.3–4.3) 0.058 
Triglycerides (mmol/L) 1.2 (0.8–1.6) 1.0 (0.7–1.4) 0.311 
Glucose (mmol/L) 5.8 (5.3–6.3) 5.8 (5.4–6.1) 0.858 
hsCRP (mg/L) 1.3 (0.7–2.8) 1.2 (0.7–2.1) 0.423 
Myeloperoxidase (ng/ml) 58.4 (35.3–110.7) 45.2 (28.0–62.6) 0.014 
Interleukin-6 (pg/ml)  1.33 (0.74–1.98) 0.95 (0.64–1.29) 0.048 
Ferritin (ng/ml) 128.0 (68.6–202.0) 92.7 (54.7–190.7) 0.110 
Adiponectin (ng/ml)  5701 ± 2890  7081 ± 3612 0.045 
Resistin (ng/ml) 3.4 (2.6–4.5) 2.8 (2.4–3.5) 0.043 
AIx@75 (%)  18.9 ± 7.2  15.1 ± 8.0 0.021 
cf-PWV (m/s)  9.7 ± 2.6  8.2 ± 1.7 0.003 
Current smoking, n (%) 13 (25) 5 (12) 0.214 
Medication, n (%) 
 Antihypertensives 48 (92) 0 (0) <0.001 
 Antiplatelets 34 (65) 0 (0) <0.001 
 Statins 28 (54) 0 (0) <0.001 
 
The values are expressed as means (± standard deviation), medians (inter-
quartile range), or prevalence (%). AIx@75, augmentation index adjusted to a 
heart rate of 75 beats per minute; CAD, coronary artery disease; cf-PWV, 
carotid–femoral pulse wave velocity; DBP, diastolic blood pressure; HDL, high-
density lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-
density lipoprotein; MAP, mean arterial pressure; SBP, systolic blood pressure; 
WBC, white blood cell. 
 
Table 7. Biomarkers of renal function and damage. 
Variable CAD patients  (n=52) 
Controls  
(n=41) p-value 
eGFR (ml/min/1,73 m2) 85 (73–97) 89 (79–93) 0.847 
S-Creatinine (μmol/L) 83.2 ± 12.3 84.0 ± 11.2 0.750 
S-Urea (mmol/L) 5.7 (4.7–7.0) 5.3 (4.5–6.0) 0.114 
Cystatin C (mg/L) 0.93 ± 0.14 0.90 ± 0.10 0.278 
NGAL (ng/ml) 74.6 (61.9–83.5) 73.7 (59.4–85.0) 0.892 
L-FABP/Creat (ng/mmol) 169.0 (121.9–228.2) 187.2 (136.5–271.3) 0.244 
KIM-1/Creat (ng/mmol) 79.6 (53.6–110.7) 85.8 (54.7–118.5) 0.636 
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The values are expressed as means (± standard deviation) or medians (inter-
quartile range). CAD, coronary artery disease; Creat, creatinine; eGFR, estimated 
glomerular filtration rate; KIM-1, kidney injury molecule-1; L-FABP, liver-type 
fatty acid-binding protein; NGAL, neutrophil gelatinase-associated lipocalin. 
 
 
Figure 3. Scatterplot showing linear correlation between carotid-femoral pulse wave 
velocity (cf-PWV) and logarithmically transformed urinary liver-type fatty acid-binding 
protein (log L-FABP) for the coronary artery disease patients (r=0.44, p=0.002).  
 
 
Table 8. Multiple regression model for the CAD group with cf-PWV as the dependent 
variable. 
Variable Regression coefficient Standard error p-value 
Mean age 0.161 0.029 <0.001 
L-FABP/Creat 0.011 0.003 0.001 
Body mass index 0.197 0.077 0.014 
KIM-1/Creat 0.013 0.006 0.023 
R2=0.584, p<0.001. CAD, coronary artery disease; cf-PWV, carotid-femoral pulse wave velocity; 
Creat, creatinine; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid-binding 
protein. 
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5.3. Serum short- and medium-chain acylcarnitines 
independently determine aortic stiffness in coronary 
artery disease patients (Paper III) 
Characteristics of the study population 
Table 9 summarizes the hemodynamic and biochemical characteristics of the 
two study groups. The groups did not differ significantly from each other with 
respect to mean age, PSBP, PDBP, CSBP, CDBP, MAP, total cholesterol, HDL 
cholesterol, LDL cholesterol, triglycerides, oxLDL, glucose or hsCRP levels. 
Significant differences between the groups were found in BMI, height, heart 
rate, cf-PWV and AIx@75, as well as in eGFR, WBC count and serum MPO, 
IL-6 and adiponectin levels.  
Table 10 presents the serum levels of acylcarnitines and other potential 
markers for vascular damage. After adjustment for multiple testing, BMI and 
use of statins, higher levels of C16:1, C18:1, hydroxybutyrylcarnitine (C3-
DC(C4-OH)), PC aa C40:6, methionine sulfoxide/methionine (Met-SO/Met, an 
indicator of systemic oxidative stress), and lower levels of lysoPC a C18:2 were 
observed in the CAD group compared to the healthy controls. 
 
Associations of arterial stiffness with metabolites 
Univariate analysis revealed that cf-PWV was significantly correlated with age 
(r=0.63, p<0.001) and eGFR (rho=–0.36, p=0.012) for the patients with CAD. 
After adjusting for multiple comparisons, cf-PWV showed correlations with 
C14, C16, C16:1, (C2+C3)/C0 (a measure of overall β-oxidation activity), C2/C0 
and the carnitine to palmitoyltransferase 1 ratio (the CPT-1 ratio) for the CAD 
group (see Table 11). For the healthy subjects, cf-PWV correlated significantly 
only with age (r=0.51, p=0.001), MAP (rho=0.51, p=0.001), AIx@75 (r=0.51, 
p=0.001) and glucose levels (rho=0.38, p=0.017). 
The component scores of factor 3 (acylcarnitines) correlated positively with 
cf-PWV for the CAD group (see Table 12). This relationship retained signi-
ficance after adjusting for potential confounders in a multiple regression model 
(R2=0.515, p<0.001, Table 13). For the control group, none of the metabolomic 
factors identified by PCA were significantly associated with the parameters of 
arterial stiffness. However, it should be noted that the metabolomic factor that 
was composed mainly of acylcarnitines showed a borderline significant corre-
lation with cf-PWV (data not shown). 
 
Arterial stiffness-associated metabolites in relation to hemodynamic and 
biochemical parameters 
Table 11 depicts the correlation coefficients of the metabolites related to arterial 
stiffness for the CAD group. After adjusting for multiple testing the following 
correlations were observed: factor 3 (acylcarnitines) showed correlations with 
HDL cholesterol, glucose and adiponectin; C14 correlated with HDL cholesterol 
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and adiponectin; C16 was correlated with PSBP, CDBP and MAP; (C2+C3)/C0 
and C2/C0 showed correlations with adiponectin; the CPT-1 ratio correlated 
with PSBP, PDBP, CSBP, CDBP, MAP and adiponectin. 
 
Table 9. Hemodynamic and biochemical parameters of the study groups. 
Variable CAD patients 
(n=52) 
Controls 
(n=40) 
p-value 
Age (years)  63.2 ± 9.2  60.3 ± 7.1 0.102 
BMI (kg/m2)  27.9 ± 3.5  26.0 ± 3.4 0.013 
Height (cm)  176.2 ± 6.4  179.4 ± 6.5 0.021 
Peripheral SBP (mmHg)   135.0 ± 14.5  129.5 ± 15.0 0.079 
Peripheral DBP (mmHg)  78.5 ± 8.0  77.8 ± 7.3 0.674 
Central SBP (mmHg)  122.7 ± 11.1  119.3 ± 13.9 0.205 
Central DBP (mmHg)  79.7 ± 7.6  78.6 ± 7.3 0.493 
MAP (mmHg) 96.0 (91.6–101.4) 92.5 (89.0–100.0) 0.095 
Heart rate (bpm)  62.8 ± 8.3  57.8 ± 7.1 0.003 
AIx@75 (%)  18.9 ± 7.2  15.3 ± 8.0 0.029 
cf-PWV (m/s)  9.7 ± 2.6  8.2 ± 1.7 0.002 
WBC count (x109/L) 6.4 (5.2–7.9) 5.1 (4.7–5.8) 0.002 
Total cholesterol (mmol/L)  5.1 ± 1.0  5.5 ± 0.9 0.136 
HDL cholesterol (mmol/L)  1.5 ± 0.4  1.6 ± 0.4 0.123 
LDL cholesterol (mmol/L) 3.2 (2.8–4.1) 3.6 (3.3–4.2) 0.076 
Triglycerides (mmol/L) 1.2 (0.8–1.6) 1.0 (0.7–1.5) 0.264 
oxLDL (U/L) 67.2 (53.5–80.7) 71.4 (59.4–90.0) 0.139 
Glucose (mmol/L) 5.8 (5.3–6.3) 5.8 (5.4–6.1) 0.81 
hsCRP (mg/L) 1.3 (0.7–2.8) 1.2 (0.7–2.1) 0.441 
MPO (ng/ml) 58.4 (35.3–110.7) 45.8 (27.7–62.6) 0.023 
IL-6 (pg/ml)  1.33 (0.74–1.98) 0.95 (0.64–1.29) 0.03 
Adiponectin (ng/ml)  5701 ± 2890  7192 ± 3585 0.043 
eGFR (ml/min/1,73 m2) 86 (71–97) 85 (79–90) 0.953 
Current smoking, n (%) 13 (24.5) 5 (12.2) 0.186 
 
The values are expressed as means ± standard deviation, medians (interquartile 
range), or prevalence (%). AIx@75, augmentation index adjusted to a heart rate 
of 75 beats per minute; BMI, body mass index; CAD, coronary artery disease; 
cf-PWV, carotid–femoral pulse wave velocity; DBP, diastolic blood pressure; 
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; 
hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; LDL, low-
density lipoprotein; MAP, mean arterial pressure; MPO, myeloperoxidase; 
oxLDL, oxidized low-density lipoprotein; SBP, systolic blood pressure; WBC, 
white blood cell.  
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Table 10. Acylcarnitines and other potential markers for vascular damage. 
Variable CAD patients (n=52) Controls (n=40) p-valuea 
C2 8.23 (6.8–10.8) 7.24 (6.42–8.74) 0.558 
C8 0.16 (0.14–0.21) 0.17 (0.14–0.24) 0.393 
C10 0.38 (0.32–0.50) 0.38 (0.31–0.52) 0.397 
C12 0.13 (0.11–0.16) 0.13 (0.11–0.16) 0.508 
C12:1 0.13 (0.11–0.17) 0.13 (0.11–0.17) 0.709 
C14 0.03 (0.03–0.04) 0.03 (0.03–0.03) 0.405 
C14:1 0.07 (0.05–0.09) 0.06 (0.04–0.08) 0.584 
C14:2 0.02 (0.02–0.03) 0.02 (0.02–0.03) 0.596 
C16 0.14 (0.11–0.15) 0.12 (0.09–0.12) 0.191 
C16:1 0.04 (0.03–0.04) 0.03 (0.02–0.03) 0.046 
C16:2 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.887 
C18:1 0.15 (0.12–0.17) 0.12 (0.10–0.14) 0.028 
C18:2 0.05 (0.04–0.06) 0.04 (0.04–0.05) 0.468 
C3-DC(C4-OH) 0.05 (0.04–0.06) 0.04 (0.04–0.05) 0.042 
(C2+C3) / C0 0.27 (0.22–0.33) 0.24 (0.21–0.30) 0.754 
C2/C0 0.25 (0.21–0.31) 0.23 (0.19–0.28) 0.724 
CPT-I ratio 0.005 (0.005–0.006) 0.005 (0.005–0.006) 0.348 
lysoPC C18:2 34.6 (28–41.65) 45.3 (40.23–60.25) 0.018 
PC aa C40:6 30.1 ± 8.9 23.9 ± 6.6 0.046 
Met-SO/Met 0.031 (0.027–0.036) 0.028 (0.024–0.032) 0.022 
 
Concentrations of all metabolites are presented as μM. The values are expressed 
as means ± standard deviation or medians (interquartile range). Data were 
adjusted for multiple testing, body mass index and statin use. Abbreviations: C2, 
acetylcarnitine; C8, octanoylcarnitine; C10, decanoylcarnitine; C12, dodecanoyl-
carnitine; C12:1, dodecenoylcarnitine, C14, tetradecanoylcarnitine; C14:1, tetra-
decenoylcarnitine; C16, hexadecanoylcarnitine; C16:1, hexadecenoylcarnitine; 
C16:2, hexadeca-dienylcarnitine; C18:1, octadecenoylcarnitine; C3-DC(C4-OH), 
3-hydroxybutyrylcarnitine; (C2+C3)/C0, (acetylcarnitine+propionylcarnitine)/ 
carnitine; (C2/C0), acetylcarnitine/carnitine; CAD, coronary artery disease; 
lysoPC a C18:2, lysophosphatidylcholine acyl C18:2; PC aa C40:6, phos-
phatidylcholine diacyl C40:6; Met, methionine; Met-SO, methionine sulp-
hoxide. The values that were significantly different between the study groups 
are shown in bold. aBenjamini-Hochberg adjusted p-value. 
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Table 11. Pearson correlation coefficients of the metabolites related to arterial stiffness for the CAD 
patients. 
 Factor 3 (acyl-
carnitines) 
C14 C16 C16:1 (C2+C3)/C0 C2/C0 CPT-1 ratio
Age  0.36 0.27 0.1 0.31 0.25 0.24 0.21 
BMI  –0.03 –0.12 0.13 0.03 –0.07 –0.07 –0.1 
PSBP  0.17 0.24 0.36* 0.15 0.28 0.27 0.54** 
PDBP  –0.08 0.07 0.32 –0.03 0.09 0.09 0.38* 
CSBP  0.2 0.21 0.31 0.19 0.28 0.27 0.53** 
CDBP  0.03 0.17 0.41* 0.1 0.17 0.18 0.4* 
MAP  0.13 0.21 0.39* 0.1 0.18 0.18 0.46** 
cf-PWV  0.49* 0.47* 0.44* 0.5* 0.45* 0.45* 0.47* 
AIx@75 –0.1 –0.3 –0.27 –0.17 –0.13 –0.13 –0.07 
WBC count  0.29 0.3 0.15 0.12 0.09 0.08 0.00 
Total cholesterol  –0.11 0.06 0.23 –0.05 –0.05 –0.05 0.18 
HDL cholesterol  0.41* 0.34* 0.1 0.29 0.19 0.19 0.15 
LDL cholesterol  –0.19 –0.01 0.21 –0.14 –0.17 –0.18 0.18 
Triglycerides  0.01 0.05 0.3 0.08 0.00 –0.01 0.02 
oxLDL  –0.00 0.13 0.29 0.12 0.07 0.07 0.24 
Glucose  0.38* 0.16 0.09 0.17 0.14 0.14 0.00 
hsCRP  –0.32 –0.11 –0.05 –0.25 –0.18 –0.18 0.09 
MPO  0.02 –0.13 –0.09 –0.1 0.02 0.03 –0.14 
IL-6  0.03 0.15 0.23 0.07 0.18 0.17 0.22 
Adiponectin  0.35* 0.44** 0.14 0.24 0.3* 0.3* 0.33* 
eGFR  –0.37 –0.2 –0.07 –0.21 –0.28 –0.28 –0.18 
Abbreviations: C14, tetradecanoylcarnitine; C16, hexadecanoylcarnitine; C16:1, hexadecenoylcarnitine; 
(C2+C3)/C0, ratio of short chain acylcarnitines to free carnitine; C2/C0, ratio of acetylcarnitine to free carnitine; 
BMI, body mass index; CAD, coronary artery disease; CPT-1 ratio, ratio of long chain acylcarnitines to free 
carnitine; CDBP, central diastolic blood pressure; cf-PWV, carotid-femoral pulse wave velocity; Chol, cholesterol; 
CSBP, central systolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; 
hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; LDL, low-density lipoprotein; MAP, mean arterial 
pressure; MPO, myeloperoxidase; oxLDL, oxidized low-density lipoprotein; PDBP, peripheral diastolic blood 
pressure; PSBP, peripheral systolic blood pressure; WBC, white blood cell. Statistically significant correlation 
coefficients are shown in bold. *Benjamini-Hochberg adjusted p-value <0.05, **Benjamini-Hochberg adjusted p-
value <0.01. 
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Table 12. Principal component analysis for the coronary artery disease group. 
Factor Description Components Eigenvalue Variance
1 
Phosphati-
dylcholines (PC) / 
sphingomyelins 
(SM) 
PC aa C42:0, PC ae C32:1, PC ae C34:0,  
PC ae C34:1, PC ae C34:2, PC ae C34:3,  
PC ae C36:1, PC ae C36:2, PC ae C36:3,  
PC ae C36:4, PC ae C38:3, PC ae C38:4,  
PC ae C38:5, PC ae C38:2, PC ae C40:2,  
PC ae C40:3, PC ae C40:4, PC ae C40:5,  
PC ae C40:6, PC ae C42:4, PC ae C42:5,  
PC ae C44:5, PC ae C44:6, SM (OH) C14:1,  
SM (OH) C16:1, SM (OH) C22:1,  
SM (OH) C22:2, SM (OH) C24:1, SM C16:0, 
Total SM, Total SM-non OH, Total SM-OH 
32.64 0.16 
2 
PCs / 
lysophosphati-
dylcholines 
(lysoPC) 
lysoPC a C24:0, lysoPC a C26:0,  
lysoPC a C26:1, lysoPC a C28:0,  
lysoPC a C28:1, PC aa C24:0, PC aa C26:0,  
PC aa C40:2, PC aa C42:6, PC ae C30:0,  
PC ae C30:1, PC ae C30:2, PC ae C32:2,  
PC ae C40:1, PC ae C42:0, PC ae C42:1,  
PC ae C42:3, PC ae C44:3 
22.02 0.10 
3 
Short-, medium-, 
and long-chain 
acylcarnitines  
C2, C8, C10, C12, C12:1, C14, C14:1,  
C14:2, C16, C16:1, C16:2, C18:1,  
C3-DC(C4-OH), (C2+C3)/C0, C2/C0 
18.06 0.09 
4 
Amino acids / 
short-chain 
acylcarnitine 
Ala, His, Ile, Leu, Phe, Pro, Thr, Trp, Tyr, Val, 
alpha-AAA, AAA, BCAA, essential AA, 
glucogenic AA, non-essential AA, total AA, C3 
12.52 0.06 
5 
PCs / lysoPC / 
polyunsaturated 
fatty acids 
(PUFA) 
lysoPC a C16:1, PC aa C34:3, PC aa C40:4,  
PC aa C40:5, PUFA 10.84 0.05 
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Table 13. Multiple regression model for the CAD patients with cf-PWV as the de-
pendent variable. 
Variable Regression coefficient Standard error p-value 
Age 0.175 0.034 <0.001 
hsCRP 0.511 0.197 0.013 
Factor 3 (acylcarnitines) 0.703 0.324 0.036 
Statin treatment –1.192 0.602 0.055 
R2=0.515, p<0.001. CAD, coronary artery disease; cf-PWV, carotid-femoral pulse wave velocity; 
hsCRP, high-sensitivity C-reactive protein. 
 
 
5.4. Serum phosphatidylcholines and 
lysophosphatidylcholines are inversely related to aortic 
stiffness, endothelial dysfunction and heart rate in 
patients with atherosclerosis (Papers III and IV) 
Baseline characteristics of the study population 
The hemodynamic and biochemical characteristics of the three study groups are 
summarized in Table 14. There were no significant differences in mean age, 
PSDP, CDBP, eGFR, ADMA, ADMA/Arg, total cholesterol, LDL cholesterol, 
glucose, insulin levels or PLT count. The patients with PAD differed 
statistically significantly from both the CAD and control subjects with respect 
to CSBP, AIx@75, cf-PWV, Arg, triglycerides, WBC count, hsCRP, IL-6 and 
to the prevalence of current smoking, antihypertensive therapy and statin use. 
Differences in the levels of PSBP, MAP, heart rate, HDL cholesterol and in the 
proportions of antiplatelet therapy only emerged from comparison to the 
controls. Higher BMI values were observed in the CAD group than in the 
patients with PAD. The CAD group also had significantly increased cf-PWV, 
heart rate, WBC count and higher prevalence of antihypertensive, antiplatelet 
and statin therapy compared to the controls.  
Table 15 depicts a selection of glycerophospholipids measured in this study. 
After adjusting for multiple comparisons, BMI, current smoking status and 
statin therapy, the PAD patients had significantly lower serum levels of PC aa 
C28:1, PC aa C30:0, PC aa C32:2, PC ae C30:0 and PC ae C34:2 than the 
healthy control group (Figure 4). In addition, lower levels of PC aa C32:2 and 
lysoPC a C18:2 were observed in the patients with CAD compared to the 
controls (Figure 4).  
 
  
53 
Relationships of arterial stiffness, endothelial dysfunction biomarkers and 
resting heart rate with glycerophospholipids 
Table 16 depicts the correlation coefficients of lysoPC a C16:0, lysoPC a C17:0, 
lysoPC a C18:0, lysoPC a C20:4 and PC aa C32:2 for the three study groups. 
After adjustment for multiple testing, cf-PWV showed negative correlation with 
serum levels of PC aa C32:2, lysoPC a C16:0 and lysoPC a C18:0 for the PAD 
patients. LysoPC a C20:4 served as an inverse correlate of cf-PWV for the CAD 
group, whereas no significant relationships between arterial stiffness and 
individual lipid species were observed for the control subjects. In multiple 
regression analysis, however, above mentioned lipids lost their significant 
relationships to cf-PWV for the both patient groups (data not shown).  
Resting heart rate correlated negatively with lysoPC a C17:0, lysoPC a 
C18:0 and PC aa C32:2 for the PAD patients, but not for the CAD patients or 
controls (Table 16). After adjusting for potential confounders, lysoPC a C17:0 
retained significance as a determinant of heart rate for the PAD group (Table 
17). 
LysoPC a C20:4, lysoPC a C16:0 and lysoPC a C18:0 were inversely related 
to ADMA/Arg only for the subjects with PAD. ADMA correlated negatively 
with lysoPC a C20:4, lysoPC a C18:0 and PC aa C32:2 for the PAD group, 
whereas lysoPC a C16:0 showed inverse relationship with ADMA for both the 
PAD and CAD patients (Table 16). Multiple regression analysis revealed, 
however, that after adjusting for potential confounders, only lysoPC a C20:4 
remained a significant determinant of both ADMA/Arg and ADMA for the 
PAD group, while lysoPC a C18:0 showed the same for the patients with CAD 
(Table 18). Finally, lysoPC a C20:4 correlated inversely with the angiographic 
score for the PAD patients (Table 16). However, this relationship lost statistical 
significance after adjustment for potential confounders (data not shown).  
 
Glycerophospholipids in relation to biochemical parameters 
After adjusting for multiple comparisons, the following relationships were 
found (Table 16): lysoPC a C16:0 showed correlations with total cholesterol, 
IL-6 and hsCRP for the PAD patients and with total cholesterol and LDL 
cholesterol for the CAD patients; lysoPC a C17:0 was correlated with IL-6 and 
hsCRP for the patients with PAD and with IL-6 and insulin for the CAD and 
control group, respectively; lysoPC a C18:0 showed correlations with total 
cholesterol, LDL cholesterol, HDL cholesterol, IL-6, hsCRP and insulin for the 
PAD group, with total cholesterol, LDL cholesterol and IL-6 for the CAD group 
and with insulin for the healthy controls; lysoPC a C20:4 correlated with IL-6 
for the PAD patients and with HDL cholesterol and insulin for the controls; PC 
aa C32:2 correlated with total cholesterol, LDL cholesterol, and IL-6 only for 
the PAD group. 
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Table 14. Baseline characteristics of study participants. 
Variable PAD patients 
(n=32) 
CAD patients 
(n=52) 
Healthy controls 
(n=40) 
p-value
Age (years)  61.7 ± 9.0  63.2 ± 9.2  60.3 ± 7.1 0.27 
BMI (kg/m2)  25.8 ± 3b  27.9 ± 3.5  26 ± 3.4 0.02 
Peripheral SBP (mmHg)  142.5 ± 17.7a  135 ± 14.5  129.5 ± 15.0 0.003 
Peripheral DBP (mmHg)  79.7 ± 7.5  78.5 ± 8.0  77.8 ± 7.3 0.59 
Central SBP (mmHg)  132.7 ± 16.5a,b  122.7 ± 11.1  119.3 ± 13.9 <0.001 
Central DBP (mmHg)  80.7 ± 7.8  79.7 ± 7.6  78.6 ± 7.3 0.51 
MAP (mmHg) 102.5 (95–107.5)a 96.0 (91.6–101.4) 92.5 (89.0–100.0) 0.01 
Heart rate (bpm) 65.5 (57.5–74.5)a 62 (58–68)a 57.3 (53–62.5) 0.001 
AIx@75 (%)  28 ± 7.4a,b  18.9 ± 7.2  15.3 ± 8.0 <0.001 
cf-PWV (m/s)c  10.5 ± 2.9a,b  9.7 ± 2.6a  8.2 ± 1.7 0.007 
ADMA (μM) 0.46 (0.42–0.57) 0.43 (0.35–0.52) 0.44 (0.37–0.49) 0.07 
Arginine (μM)  122.7 ± 22.7a,b  102.4 ± 21  99.4 ± 22.3 <0.001 
ADMA/arginine 0.004 (0.003–0.005) 0.004 (0.003–0.005) 0.005 (0.003–0.005) 0.36 
Total cholesterol (mmol/L)  5.3 ± 1.1  5.1 ± 1.0  5.5 ± 0.9 0.43 
HDL cholesterol (mmol/L)  1.3 ± 0.4a  1.5 ± 0.4  1.6 ± 0.4 0.003 
LDL cholesterol (mmol/L) 3.4 (2.7–4.2) 3.2 (2.8–4.1) 3.6 (3.3–4.2) 0.19 
Triglycerides (mmol/L) 1.6 (1.4–2.1)a,b 1.2 (0.8–1.6) 1.0 (0.7–1.5) 0.002 
Glucose (mmol/L) 5.5 (5.2–5.9) 5.8 (5.3–6.3) 5.8 (5.4–6.1) 0.07 
Insulin (IU/ml) 4.9 (3.1–8.2) 5.8 (4.4–8.8) 4.9 (3.3–7.5) 0.13 
WBC count (x109/L) 8.2 (6.3–9.1)a,b 6.4 (5.2–7.9)a 5.1 (4.7–5.8) <0.001 
Platelet count (x109/L) 240 (192–298) 213 (182–247) 210 (186–239) 0.18 
hsCRP (mg/L) 3.2 (1.1–6.8)a,b 1.3 (0.7–2.8) 1.2 (0.7–2.1) <0.001 
Interleukin-6 (pg/ml) 2.81 (1.14–5.57)a,b 1.33 (0.74–1.98) 0.95 (0.64–1.29) <0.001 
Resistin (ng/ml) 3.5 (2.6–4.4) 3.4 (2.6–4.5) 2.8 (2.3–3.7) 0.18 
eGFR (ml/min/1,73 m2) 89.5 (76–96) 86 (71–97) 85 (79–90) 0.39 
Angiographic score (AU)  27.8 ± 7.1 ND ND ND 
Current smoking, n (%) 25 (78)a,b 13 (25) 5 (13) <0.001 
Medication, n (%) 
Antihypertensive therapy 19 (59)a,b 48 (92)a 0 (0) <0.001 
Antiplatelet therapy 13 (41)a 34 (65)a 0 (0) <0.001 
Statin therapy 7 (22)a,b 28 (54)a 0 (0) <0.001 
a = <0.05 vs control group 
b = <0.05 vs CAD group 
c = cf-PWV has been adjusted for MAP 
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The values are presented as means ± standard deviation, medians (interquartile 
range), or prevalence (%). ADMA, asymmetric dimethylarginine; AIx@75, 
augmentation index adjusted to a heart rate of 75 beats per minute; BMI, body 
mass index; CAD, coronary artery disease; cf-PWV, carotid–femoral pulse 
wave velocity; DBP, diastolic blood pressure; eGFR, estimated glomerular 
filtration rate; HDL, high-density lipoprotein; hsCRP, high-sensitivity C-
reactive protein; LDL, low-density lipoprotein; MAP, mean arterial pressure; 
PAD, peripheral arterial disease; SBP, systolic blood pressure; WBC, white 
blood cell. 
 
Table 15. Phosphatidylcholine and lysophosphatidylcholine levels among the study 
groups. 
Metabolite PAD patients (n=32) 
CAD patients 
(n=52) 
Healthy controls 
(n=40) p-value 
lysoPC a C16:0 127 (117–152) 136 (122–156) 148 (128–159) 0.353 
lysoPC a C17:0 2.2 (1.7–2.4) 2.4 (1.8–2.9) 2.6 (2.1–3.5) 0.325 
lysoPC a C18:0 40.9 (33–46.6) 40.3 (34.4–49.2) 42.2 (37.7–53.5) 0.586 
lysoPC a C18:1 25.9 (21.7–35.6) 30 (23.8–34.6) 34.1 (28.2–60.3) 0.325 
lysoPC a C18:2 34 (26.2–41.9) 34.6 (28–41.7)a 45.3 (40.2–60.3) 0.028 
lysoPC a C20:3 2.6 (2.2–3.2) 2.4 (2–3.2) 2.9 (2.4–3.7) 0.402 
lysoPC a C20:4 8.7 (7.3–10.6) 9.1 (7.4–10.4) 8.6 (7.1–11.2) 0.842 
PC aa C28:1 2.8 (2.3–3.1)a 3 (2.7–3.5) 3.5 (3–4.2) 0.048 
PC aa C30:0 3.2 (2.6–3.8)a 3.3 (2.8–4) 4.3 (3.3–5.5) 0.028 
PC aa C32:2 2.1 (1.5–2.8)a 2.5 (1.9–3.1)a 3.4 (2.7–5) 0.006 
PC aa C34:3 10.1 (7.4–11.4) 9.8 (7.7–12) 13 (10.5–15.4) 0.094 
PC aa C36:6 0.69 (0.51–0.98) 0.89 (0.61–1.1) 0.89 (0.7–1.2) 0.353 
PC aa C40:5 7.3 (6.8–9.5) 7.2 (6–8.8) 6.5 (5.3–8) 0.404 
PC ae C30:0 0.31 (0.23–0.38)a 0.36 (0.27–0.45) 0.44 (0.35–0.6) 0.028 
PC ae C34:2 7.1 (5.7–9)a 8 (6.7–9.9) 9.6 (8–11.2) 0.048 
PC ae C34:3 4.9 (3.7–5.8) 5.5 (4.3–6.5) 6 (5–6.9) 0.325 
PC ae C36:3 4.8 (3.8–5.9) 5.5 (4.5–6.5) 6.2 (5–6.8) 0.13 
PC ae C36:4 10.6 (9.5–13.1) 13.2 (10–15.7) 12.5 (10.1–14.4) 0.342 
PC ae C38:0 1.5 (1.3–2) 1.8 (1.3–2.2) 1.7 (1.5–2.2) 0.483 
PC ae C38:3 3.1 (2.7–3.4) 2.9 (2.5–3.4) 3.2 (2.7–3.5) 0.664 
PC ae C40:1 1.1 (1–1.5) 1.2 (1.1–1.5) 1.3 (1.1–1.7) 0.325 
PC ae C42:1 0.42 (0.36–0.65) 0.42 (0.36–0.62) 0.46 (0.37–0.71) 0.559 
a = <0.05 vs control group 
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Concentrations of all metabolites are presented as μM. The values are expressed 
as medians (interquartile range). Abbreviations: a, acyl; aa, diacyl; ae, acyl-alkyl; 
CAD, coronary artery disease; lysoPC, lysophosphatidylcholine; PAD, peripheral 
arterial disease. *p-values were adjusted for body mass index, current smoking 
status and statin use. Benjamini-Hochberg procedure was used to account for 
multiple testing. A corrected p-value <0.05 was considered to be statistically 
significant. 
 
 
 
Figure 4. A bar chart showing the median concentrations of selected phosphati-
dylcholine (PC) and lysophosphatidylcholine (lysoPC) species across the three study 
groups. *p-values were adjusted for body mass index, current smoking status and statin 
use. Benjamini-Hochberg procedure was used to account for multiple testing. A 
corrected p-value <0.05 was considered to be statistically significant. Abbreviations: 
CAD, coronary artery disease; PAD, peripheral arterial disease. 
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Table 16. Spearman’s rank correlation coefficients between clinical characteristics and 
selected glycerophospholipids for the three study groups. 
  lysoPC a C16:0 
lysoPC a 
C17:0 
lysoPC a 
C18:0 
lysoPC a 
C20:4 
PC aa 
C32:2 
PAD patients (n=32) 
cf-PWV –0.57* –0.16 –0.45* –0.28 –0.6** 
Heart rate –0.34 –0.56** –0.45* –0.3 –0.47* 
Angiographic score –0.34 –0.05 –0.2 –0.41* 0.01 
ADMA –0.49* –0.24 –0.44* –0.5* –0.42* 
ADMA/Arginine –0.47* –0.15 –0.38* –0.44* –0.21 
Total cholesterol 0.54* 0.09 0.58* 0.16 0.66** 
LDL cholesterol 0.45 –0.01 0.47* 0.07 0.56** 
HDL cholesterol 0.29 0.13 0.47* 0.07 0.32 
Interleukin-6 –0.54* –0.65** –0.6** –0.49* –0.44* 
hsCRP –0.42* –0.54** –0.42* –0.18 –0.38 
Insulin –0.38 –0.22 –0.42* –0.38 –0.31 
CAD patients (n=52) 
cf-PWV –0.08 –0.04 –0.11 –0.36* –0.04 
Heart rate –0.07 –0.18 –0.12 –0.26 –0.13 
ADMA –0.32* –0.04 –0.26 –0.15 0.01 
ADMA/Arginine –0.28 –0.08 –0.22 –0.1 0.03 
Total cholesterol 0.56** 0.16 0.55** 0.22 0.37 
LDL cholesterol 0.47** 0.11 0.55** 0.24 0.27 
HDL cholesterol 0.11 0.12 –0.04 –0.12 0.27 
Interleukin-6 –0.14 –0.36* –0.31* –0.19 –0.21 
hsCRP –0.09 –0.21 –0.11 0.05 –0.06 
Insulin –0.07 –0.1 –0.06 –0.24 0.17 
Healthy controls (n=40) 
cf-PWV 0.18 0.1 0.1 –0.06 0.05 
Heart rate –0.01 –0.27 –0.13 0.05 0.23 
ADMA –0.18 –0.2 –0.2 –0.09 –0.15 
ADMA/Arginine –0.21 –0.18 –0.2 –0.08 –0.13 
Total cholesterol 0.25 0.22 0.31 0.27 0.13 
LDL cholesterol 0.13 0.13 0.26 0.12 0.1 
HDL cholesterol 0.21 0.34 0.29 0.4* 0.1 
Interleukin-6 0.02 –0.26 –0.2 0.01 –0.19 
hsCRP –0.19 –0.33 –0.17 0.07 –0.01 
Insulin –0.24 –0.43* –0.38* –0.37* 0.09 
Abbreviations: a, acyl; aa, diacyl; ADMA, asymmetric dimethylarginine; ae, acyl-alkyl; CAD, 
coronary artery disease; cf-PWV, carotid-femoral pulse wave velocity; HDL, high-density 
lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; lysoPC, 
lysophosphatidylcholine; PAD, peripheral arterial disease; PC, phosphatidylcholine. Statistically 
significant correlation coefficients are presented in bold. *Benjamini-Hochberg adjusted p-value 
<0.05, **Benjamini-Hochberg adjusted p-value <0.01. 
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Table 17. Multiple regression model for PAD group with resting heart rate as the 
dependent variable. 
Variable Regression coefficient Standard error p-value 
LysoPC a C17:0 –7.962 2.302 0.002 
Glucose 9.192 3.110 0.006 
Mean arterial pressure 0.309 0.138 0.033 
R2=0.593, p<0.001. LysoPC, lysophosphatidylcholine; PAD, peripheral arterial disease. 
 
 
Table 18. Multiple regression analyses for the PAD and CAD patients with ADMA/Arg 
and ADMA as dependent variables. 
Variable Regression coefficient Standard error p-value 
PAD patients 
ADMA/Arga 
LysoPC a C20:4 –0.0002 6.7–5 0.006 
Mean arterial pressure 4.6–5 1.7–5 0.012 
LDL cholesterol 0.0004 0.0002 0.025 
ADMAb 
LysoPC a C20:4 –0.024 0.009 0.010 
LDL cholesterol –0.034 0.023 0.155 
Mean age 0.002 0.003 0.426 
CAD patients 
ADMA/Argc 
Platelets –9.7–6 3.0–6 0.005 
Interleukin-6 7.4–5 2.6–5 0.008 
LysoPC a C18:0 –4.9–5 2.1–5 0.022 
ADMAd 
Resistin 0.031 0.012 0.010 
LysoPC a C18:0 –0.004 0.002 0.013 
LDL cholesterol 0.028 0.016 0.086 
aR2=0.388, p=0.001; bR2=0.300, p=0.005; cR2=0.273, p<0.001; dR2=0.162, p=0.009. ADMA, 
asymmetric dimethylarginine; Arg, arginine; CAD, coronary artery disease; LDL, low-density 
lipoprotein; lysoPC, lysophosphatidylcholine; PAD, peripheral arterial disease. 
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6. DISCUSSION 
6.1. Relationships between biomarkers of renal damage, 
arterial stiffness and inflammation in atherosclerotic 
patients without moderate to severe chronic kidney 
disease (Papers I and II) 
Besides its potential use as a mere reflector of kidney injury (Neiman et al. 
2011), FBLN-1 serves independent physiological and pathophysiological roles 
and may directly participate in the development of atherosclerosis and vascular 
dysfunction (Argraves et al. 2009; Cangemi et al. 2011; Kostka et al. 2001; 
Laugesen et al. 2013). In the present thesis, Paper I demonstrated independent 
association between serum FBLN-1 concentration and AIx@75 in subjects with 
PAD. Moreover, significantly higher FBLN-1 and AIx@75 levels were found in 
these patients compared to the healthy controls. Although we also detected a 
statistically non-significant increase in circulating levels of FBLN-1 in patients 
with CAD, no correlation was found between this extracellular protein and 
AIx@75 for this group. These findings may suggest that the relationship between 
FBLN-1 and left ventricular late-systolic loading becomes more apparent in 
distal diffuse atherosclerosis commonly seen in patients with PAD. Yet, it must 
be noted that the same relationship was recently demonstrated in a group of 210 
CAD patients (Hansen and Rasmussen 2015). Thus, the lack of correlation 
between FBLN-1 and AIx@75 among the CAD patients in our study might 
have also been due to the relatively small sample size. Previous studies in 
subjects with type 2 diabetes and CKD showed that FBLN-1 correlated with cf-
PWV and unadjusted AIx, respectively, although the latter relationship did not 
retain statistical significance in multivariate analysis (Laugesen et al. 2013; 
Scholze et al. 2013).  
A significant correlation between serum FBLN-1 and biochemical markers 
of inflammation was also observed. Serum resistin emerged as an independent 
determinant of FBLN-1 concentration in the PAD patients. Increased serum 
levels of this adipokine have previously been associated with insulin resistance 
and atherosclerosis (Reilly et al. 2005; Syed Ikmal et al. 2013). Elevated 
resistin levels are also associated with CAD and the risk of CV death (Sinan et 
al. 2014). Interestingly, in our study, no significant differences between groups 
were found in the concentrations of this pro-inflammatory adipokine. These 
results may imply that the correlation between FBLN-1 and resistin for the PAD 
group may have appeared due to more extensive vascular injury and increased 
FBLN-1 levels in these patients compared to the CAD and control groups. 
Higher WBC count was also present in both the PAD and CAD patients. 
High WBC count may reflect a chronic inflammatory state and have been 
reported to affect vascular function in individuals with low CV risk (Li et al. 
2013). Leukocytes play an important role in the genesis of atherosclerosis as 
they represent the predominant cell population involved in inflammation 
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(Shaykhiev and Bals 2007). Univariate correlation between WBC count and 
serum FBLN-1 was found in the PAD and CAD patients, and it retained 
statistical significance in multivariate analysis in the CAD group. This could 
suggest that the systemic inflammatory state, common in atherosclerosis, has an 
effect on FBLN-1 serum levels. Whether the same correlation is observed in 
non-atherosclerotic patients with high WBC count remains to be elucidated. 
Increased PLT aggregation and activation have been previously observed in 
patients with PAD (Robless et al. 2003). Furthermore, thrombotic events like 
MI and stroke are the common causes of morbidity and mortality in these patients 
(Golomb et al. 2006). The potential role of FBLN-1 in hemostasis and throm-
bosis has been addressed as well. Several studies indicate that FBLN-1 can 
mediate PLT adhesion by binding fibrinogen, is able to incorporate into fibrin 
clots and accumulates in human atherosclerotic lesions (Argraves et al. 2009). 
In accordance with the role of FBLN-1 in PLT adhesion, a correlation between 
FBLN-1 and PLT count in the PAD group was found in the present study. 
Furthermore, PAI-1, an important protein in fibrinolysis as well as in tissue 
remodeling, correlated with FBLN-1 in the control group (Ghosh and Vaughan 
2012). Although interesting, the exact mechanisms behind these findings cannot 
be explained within the scope of our study.  
In the current thesis, Paper II revealed correlations between aortic stiffness 
and markers of both renal function and tubular damage in the symptomatic 
CAD patients. The novel findings that urinary L-FABP and KIM-1 are indepen-
dently associated with cf-PWV in CAD extend our current knowledge of these 
proteins and may partially explain their value as biomarkers for CV prognosis 
in different study populations (Araki et al. 2013; Carlsson et al. 2013, 2014; 
Matsumori et al. 2012).  
L-FABP is involved in the fatty acid uptake, intracellular transport and 
metabolism (Antonenkov et al. 2006; Murphy et al. 1996). In the case of kidney 
damage, the expression of L-FABP in the proximal tubular cells is upregulated 
(Ferguson et al. 2010; Noiri et al. 2009; Oyama et al. 2005; Yamamoto et al. 
2007). It has been previously shown that the estimated contribution of serum  
L-FABP to urinary L-FABP levels is only 3%, hence the L-FABP that is found 
in urine is produced primarily by the tubular cells (Imai et al. 2015; Kamijo et 
al. 2006). Interestingly, the mean urinary levels of this protein were moderately 
lower in the subjects with CAD compared to the controls in our study, however 
this difference was not statistically significant. Since L-FABP has been reported 
as a renoprotective endogenous antioxidant, it can be hypothesized that its lower 
levels may reflect reduced kidney protection in atherosclerotic patients without 
moderate to severe CKD (Kanaguchi et al. 2011; Matsui et al. 2011; Mori et al. 
2014). 
In the presence of increased arterial stiffness, the kidneys are particularly 
susceptible to the damage resulting from high pulsatile pressure and flow 
(Mitchell 2008). We observed elevated values of cf-PWV and AIx@75 for the 
subjects with CAD. Furthermore, besides its independent association with  
L-FABP and KIM-1, cf-PWV was also correlated with serum creatinine, CysC 
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and eGFR in these patients, but not in the healthy controls. Although the type of 
causality could not be determined, these findings support the view that increased 
arterial stiffness (and thus high pulsatile pressure and flow) contributes to renal 
dysfunction and propose that urinary L-FABP and KIM-1 may serve as novel 
biomarkers that reflect this relationship even in the early stages of renal 
damage. However, it should be noted that this relationship might be bidirec-
tional and could also be affected by some other pathophysiological processes. 
We acknowledge that eGFR tends to be less accurate at levels above 
60 ml/min per 1.73 m2 (Levey et al. 2009). However, the Chronic Kidney Disease 
Epidemiology Collaboration creatinine equation used in the current work 
performs better than the Modification of Diet in Renal Disease Study formula, 
especially at higher GFR levels (Levey et al. 2009; Stevens et al. 2010). When 
we performed post hoc subgroup analyses based on eGFR levels L-FABP 
showed a strong and CysC a moderate correlation with cf-PWV for the subgroup 
of CAD patients with eGFR between 60 and 89 mL/min/1.73 m2, whereas none 
of the measured kidney biomarkers retained as significant correlates of aortic 
stiffness for the patients with eGFR ≥ 90 mL/min/1.73 m2. Although these 
findings are potentially interesting, larger studies with pre-specified subgroup 
analyses are warranted to explore these possible differences between CAD 
patients with eGFR ≥ 90 mL/min/1.73 m2 and those with eGFR between 60 and 
89 mL/min/1.73 m2. 
The relationships between kidney biomarkers and cf-PWV did not change in 
the control group after dividing subjects into two subgroups based on eGFR 
(data not shown). The lack of correlations in the healthy subjects might be due 
to their better preserved vascular function and reduced inflammation compared 
to the CAD patients. Indeed, decreased serum adiponectin, higher WBC count 
and elevated IL-6, MPO and resistin levels indicated systemic inflammation in 
the CAD group when juxtaposed with the healthy controls. Previous findings 
suggest that elevated resistin may be especially undesirable in the case of 
reduced adiponectin levels (Machii 2012; Spoto et al. 2013). Although the true 
function of resistin still remains to be established, it seems to play significant 
regulatory roles in various biological processes including low-grade inflam-
mation and atherosclerosis (Jamaluddin et al. 2012).  
Urinary KIM-1 showed a borderline significant correlation with cf-PWV for 
the CAD patients. However, this relationship reached statistical significance 
after adjusting for potential confounders. KIM-1 functions as a transmembrane 
phosphatidyl serine receptor that recognizes apoptotic cells and has also been 
suggested as an early marker for tubular damage (Sabbisetti et al. 2014; 
Torregrosa et al. 2015). A recent study in mice demonstrated that by facilitating 
the phagocytic process, KIM-1 might have a protective anti-inflammatory role 
in the early stages of AKI (Yang et al. 2015). In our work, urinary KIM-1 
correlated positively with serum adiponectin and inversely with ferritin for the 
CAD patients but not for the controls. Although the association between KIM-1 
and aortic stiffness in the CAD group was weak, it reveals a novel aspect of this 
prognostic biomarker and deserves further study.  
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Several correlations also emerged between serum NGAL and indices of 
kidney function and inflammation. Positive relationships with WBC count and 
resistin for both groups are in line with the view that serum NGAL could serve 
as an inflammatory marker in a range of clinical settings (Gümüs et al. 2014; 
Naudé et al. 2013; Smertka et al. 2014). This lipocalin is expressed by neutro-
phils and various epithelial cells and has received attention as an AKI marker 
because of its early upregulation in the damaged tubular cells (Haase et al. 2009; 
Liebetrau et al. 2013). High expression of NGAL in atheromatous plaques and 
its role in inflammation might explain the previous finding that this biomarker 
could prove useful in discriminating between unstable and stable CAD patients 
(Hemdahl et al. 2006; Kafkas et al. 2012). However, serum NGAL was not 
related to arterial stiffness in the current study. Further investigations will 
evidently determine its true role in inflammation and vascular damage. 
 
 
6.2. Arterial stiffness, hemodynamics and serum 
acylcarnitines in patients with coronary artery disease 
(Paper III) 
Besides the lipid-related classical CV risk markers, a range of intermediates and 
products of lipid and amino acid metabolism have emerged as potential indi-
cators of CVD. Association between tyrosine and altered arterial function in 
patients with PAD has been previously shown by our group (Zagura et al. 
2015). Moreover, a large prospective study of three population-based cohorts 
identified phenylalanine – an immediate precursor of tyrosine – and some 
unsaturated fatty acids as potential biomarkers for CV risk (Würtz et al. 2015). 
These findings indicate that metabolomic studies may help gain a deeper under-
standing of the molecular mechanisms of CVD. In addition, although different 
fractions of cholesterol and triglycerides are routinely estimated in clinical 
practice, they actually cover only a limited part of whole-body lipid meta-
bolism. Therefore, more detailed metabolomic analysis would hopefully lead to 
the discovery of sensitive and specific novel lipid-related markers for vascular 
injury and CVD risk. 
Paper III demonstrated for the first time, to our knowledge, that the serum 
acylcarnitine profile is independently associated with aortic stiffness in patients 
with CAD. While some previous studies have shown the predictive value of 
acylcarnitines on CV events (Rizza et al. 2014; Shah et al. 2012), the mecha-
nisms behind this relationship remain poorly understood. Our findings link 
medium- and long-chain acylcarnitines to cf-PWV and may therefore offer one 
plausible explanation for the association between these metabolic intermediates 
and CVD risk. 
When the rate of the release of fatty acids from adipose tissue triglycerides 
overpowers the capacity of β-oxidation, or when the oxidative metabolism of 
fatty acids in mitochondria is impaired, acylcarnitine levels in the blood will 
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increase. Therefore, it can be hypothesized that elevated levels of medium- and 
long-chain acylcarnitines in CAD patients compared to controls may reflect the 
alterations present at any step in this metabolic pathway (release of fatty acids, 
their transport into mitochondria, and oxidation in mitochondria). Changes in 
the activity of the enzymes that regulate long-chain fatty acid transport (e.g. 
carnitine-palmitoyltransferases 1 (CPT-1) and 2 (CPT-2)) could also occur 
under hypoxic conditions. Interestingly, we found a positive relationship between 
the CPT-1 ratio and cf-PWV for the patients with CAD. The CPT-1 ratio 
reflects the activity of CPT-1 which is a rate-limiting enzyme for β-oxidation of 
long-chain fatty acids (Michal 1999). In addition, positive correlations between 
cf-PWV, (C2+C3)/C0 and C2/C0 for the CAD group also suggest a potential 
link between arterial stiffness and β-oxidation activity for these patients. 
Besides its association with arterial stiffness, the PCA-derived factor 3 
(acylcarnitines) showed significant correlations with HDL cholesterol, glucose 
and adiponectin levels for the CAD group. More specifically, C16 correlated 
with PSBP, CDBP and MAP, and therefore seems to reflect changes both in 
hemodynamics and aortic stiffness for these patients. Previous studies have 
demonstrated that C16 might be involved in the pathology of cardiac ischemia. 
Its accumulation in the myocardial sarcolemma during hypoxia can contribute 
towards cardiac cell damage and dysfunction (Dhalla et al. 1991; McHowat et 
al. 1993; Wu et al. 1993). Moreover, high plasma levels of C16 have recently 
been associated with degree of heart failure (Ueland et al. 2013). The same 
study reported that C16 was also independently associated with all-cause 
mortality for these patients (Ueland et al. 2013). However, little is known about 
the role of C16:1 in CVD. In the current study, C16:1 levels were higher in the 
CAD patients compared to the controls and showed the strongest association 
with arterial stiffness among individual acylcarnitines for the patient group. 
C16:1 also seems to be a positive marker for adiponectin levels.  
The clear association between serum acylcarnitines and arterial stiffness 
observed for the CAD group is intriguing, yet their true role in vascular injury 
remains unknown. It is possible that higher serum levels of medium- and long-
chain acylcarnitines merely reflect serious cardiac ischemia which is the result 
of more severe atherosclerosis and increased arterial stiffness. On the other 
hand, accumulating acylcarnitines can alter insulin signaling and may therefore 
lead to arterial stiffness through induction of insulin resistance (Schooneman et 
al. 2013; Westerbacka and Yki-Jarvinen 2002). Moreover, insulin resistance 
itself is accompanied with an increased release of free fatty acids into the 
bloodstream (Delarue and Magnan 2007). Finally, it can also be hypothesized 
that acylcarnitines play a direct causal role in vascular injury, however, the true 
underlying mechanisms of this remain to be established in future experiments. 
Several other metabolic variables showed significant positive (C2, C8, C12, 
C12:1, C14:1, C14:2, C18:1, C18:2, PC aa C42:0, PC aa C42:2) and negative 
(lysoPC a C20:4) correlations with cf-PWV for the CAD patients before adjusting 
for multiple comparisons. Apparently, most of these variables were medium- 
and long-chain acylcarnitines. Interestingly, higher levels of lysoPC a C20:4 
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were shown to be associated with lower CVD incidence in a previous study by 
Fernandez and colleagues (Fernandez et al. 2013). Although the above relation-
ships between cf-PWV and metabolites lost statistical significance after cor-
recting for multiple testing bias, these findings further support the association 
between medium- and long-chain acylcarnitines and arterial stiffness reported in 
the present thesis. 
 
 
6.3. Arterial stiffness, endothelial dysfunction and resting 
heart rate in relation to serum phosphatidylcholines and 
lysophosphatidylcholines in patients with atherosclerosis 
(Papers III and IV) 
Papers III and IV revealed alterations in both PC and lysoPC profiles in the 
atherosclerotic patients compared to the healthy controls. We also showed that 
PAD and CAD patients can differ in the way their serum PC and lysoPC levels 
relate to other biochemical and functional parameters. Thus, despite many 
similarities, these patient groups cannot be presumed equivalent.  
Paper III showed significantly lower concentrations of lysoPC C18:2 in the 
patients with CAD compared to healthy subjects. This finding is in line with a 
recent large-scale metabolomic profiling study that demonstrated an inverse 
relationship between lysoPC C18:2 and CAD (Ganna et al. 2014). However, the 
authors suggested that the association was likely to not be causal. We also 
observed increased concentrations of PC aa C40:6 in the patients with CAD. 
The levels of PC aa C40:6 correlated with total cholesterol for both study 
groups, but a positive relationship with HDL cholesterol was observed only for 
the CAD group. Interestingly, in a recent prospective study, PC aa C40:6 and 
lysoPC C18:2 were independently associated with decreased risk of type 2 dia-
betes (Floegel et al. 2013). In our study, PC aa C40:6 showed positive corre-
lation and lysoPC C18:2 showed negative correlation with cf-PWV among the 
CAD patients, however, these relationships lost statistical significance after 
adjustment for multiple comparisons. Yet both metabolites might prove their 
potential as biomarkers of vascular injury in future studies with larger sample 
size. 
Paper IV demonstrated a highly significant correlation between aortic stiff-
ness and PC aa C32:2 for the patients with PAD, but not for the CAD or control 
group. However, after adjustment for total cholesterol and several other poten-
tial confounders, this relationship lost statistical significance (data not shown). 
It should be noted that before controlling for multiple comparisons (to reduce 
the risk of type I error), several other PCs (PC aa C34:3, PC aa C40:5, PC ae 
C36:3, PC ae C36:4, PC ae C38:0, PC ae C38:3 and PC ae C40:1), besides PC 
aa C32:2, correlated negatively with cf-PWV for the subjects with PAD. 
Although significantly lower levels of PC aa C32:2 were found in both the PAD 
and CAD patients compared to the controls, aortic stiffness did not appear to 
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correlate with this lipid for the subjects with CAD. However, before adjustment 
for multiple testing, lysoPC a C18:2 and lysoPC a C20:4 correlated negatively 
and PC aa C40:6 and PC aa 42:2 correlated positively with arterial stiffness for 
these patients (data not shown).  
PCs and lysoPCs serve as reservoirs and transporters of glycerophospholipid 
components (fatty acids, phosphate, glycerol and choline) (Schmitz and Rueb-
saamen 2010). Depletion of these lipid classes might therefore lead to decreased 
availability of choline which is an important nutrient for humans (Zeisel and Da 
Costa 2009). Besides being used in membrane phospholipid synthesis, choline 
is also an essential precursor for the neurotransmitter acetylcholine. Paper IV 
reported elevated resting heart rate and lower levels of several PCs and lysoPCs 
in the patient groups compared to the healthy controls. Interestingly, PC and 
lysoPC molecular species correlated negatively with heart rate for both the 
patients with PAD and CAD (lysoPC a 17:0, PC aa C30:0, PC aa C32:2, PC aa 
C36:6 and lysoPC a 18:2, PC ae C34:3, PC ae C40:1, PC ae C42:1, respectively) 
but not for the controls (data not shown). After adjusting for multiple testing, 
lysoPC a 17:0 remained a significant correlate of heart rate for the subjects with 
PAD. This relationship was independent of potential confounding variables. 
Nevertheless, one can only speculate on the reasons why the patients with lower 
serum PC and lysoPC levels tended to have increased heart rate in our study. 
Some of these lipids may have chronotropic effects via direct or indirect modu-
lation of cardiac ion-channels (Kim and Clapham 1989; Wallert et al. 1991). A 
study of a rat heart model showed decreases of heart rate and left ventricular 
developed pressure after perfusion with exogenous lysoPC (Watanabe and 
Okada 2003). Thus it seems that there might be a causal rather than a simple 
correlational relationship between lysoPCs and heart rate. An imbalance between 
sympathetic and parasympathetic activity plays a prognostic role in patients 
with CVD (Oberhauser et al. 2001) and resting heart rate is an independent 
predictor of morbidity and mortality in the general population as well as in 
several types of CVDs (Hjalmarson 1998; Zhang et al. 2016). Since decreased 
heart rate is characteristic of acetylcholine effects, lower PC and lysoPC levels 
may reflect (or give rise to) decreased parasympathetic drive to the heart. Yet it 
should be noted that serum choline levels were not measured in this study. It is 
also plausible that reduced physical performance, inflammation and pain caused 
by limb or myocardial ischemia lead to increased sympathetic drive and heart 
rate but lower PC and lysoPC levels in symptomatic patients with atheroscle-
rosis. Evidently, further studies are warranted to clarify the mechanisms behind 
our findings. 
There is a considerable amount of evidence from ex vivo studies that lysoPCs 
induce ED and regulate vascular tone (Kugiyama et al. 1999; Murohara et al. 
1996; Zhang et al. 2009). However, less is known about serum levels of 
individual molecular species of this lipid class in ED. In the present thesis, 
Paper IV demonstrated relationships between serum lysoPCs and surrogate 
markers of ED (ADMA and ADMA/Arg). In univariate analysis, after adjusting 
for multiple testing, lysoPC a C16:0, lysoPC a C18:0, lysoPC a C18:1, lysoPC a 
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C20:3 and lysoPC a C20:4 remained significant negative correlates of ADMA 
for the subjects with PAD while lysoPC a C16:0 and lysoPC a 20:3 showed 
inverse correlation also with ADMA/Arg for these patients. Additionally, 
lysoPC a C16:0 continued to be a significant negative correlate of ADMA for 
the CAD patients, whereas no such relationships were found for the healthy 
controls. In multiple regression analysis, however, lysoPC a C20:4 and lysoPC a 
C18:0 remained significant determinants of ED for the PAD and CAD patients, 
respectively. These findings seem paradoxical in the light of previous in vitro 
studies. However, extrapolating results from ex vivo studies to the whole 
organism can prove challenging. Plasma concentrations of several lysoPCs have 
previously been found to be inversely correlated with CRP in obesity (Heimerl 
et al. 2014). Furthermore, lower levels of lysoPCs have also been found in 
patients with cancer (Taylor et al. 2007) and sepsis (Drobnik et al. 2003). In our 
study, the CAD patients had the highest BMI but rarely the lowest levels of 
individual lysoPC species across the three study groups. This suggests that 
inflammation (particularly pronounced in PAD patients) might be a more 
probable cause of the differences in the levels of these lipids. It has been 
speculated that lower serum levels of lysoPCs in CAD patients might result 
from their more efficient removal from blood into tissues, either in the form of 
oxLDL or directly from albumin (Meikle et al. 2011). A greater burden of 
atherosclerosis, and hence worse ED, could therefore coincide with lower serum 
levels of these lipids. This hypothesis is partially supported by the inverse 
relationship between lysoPC a C20:4 and angiographic score for the lower 
extremities observed for the PAD patients in our study. In multivariate analysis, 
however, this correlation lost its statistical significance (data not shown). 
 
 
6.4. Possible reasons for observed differences between 
coronary artery disease patients and peripheral arterial 
disease patients (Papers I and IV) 
Both CAD and PAD patients were included in Papers I and IV. As expected, 
increased arterial stiffness and inflammation were observed in these athero-
sclerotic patients compared to the healthy controls (Papers I and IV). In addition, 
patients with PAD showed worse arterial function than those with CAD. Stiffer 
arteries may at least partially result from their more pronounced inflammatory 
status. Indeed, higher WBC count and elevated levels of hsCRP (Papers I and 
IV) and IL-6 (Paper IV) were observed in the subjects with PAD. It has been 
previously reported that CAD patients with comorbid PAD have a larger overall 
burden of atherosclerosis and inflammation, worse endothelial function, in-
creased arterial stiffness and decreased physical activity compared to patients 
with CAD alone (Grenon et al. 2013). Moreover, critical lower extremity 
ischemia frequently occurs with considerable tissue loss (Aronow 2007), which 
can alter the levels of circulating metabolites and other biochemical markers.  
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PAD patients are also less likely to receive antihypertensive and statin 
therapy (Rice and Lumsden 2006). Accordingly, we found significantly lower 
rates of antihypertensive medication (50% vs. 95% in Paper I and 59% vs. 92% 
in Paper IV) and statin use (18% vs. 53% in Paper I and 22% vs. 54% in Paper 
IV) for the PAD group. Furthermore, cigarette smoking is generally more pre-
valent in these patients and it has been shown to be a stronger risk factor for 
PAD than for CAD (Shammas 2007) (72% vs. 21% in Paper I and 78% vs. 25% 
in Paper IV). Smoking promotes oxidative stress, ED and alters lipid meta-
bolism, among others (Lu and Creager 2004; Shammas 2007).  
Finally, lower BMI was found in patients with PAD compared to those with 
CAD (Papers I and IV). A previous large-scale study in community-living older 
adults demonstrated that smoking, poor health status, weight loss, and PAD 
often coexist in older persons, while higher BMI was associated with sub-
sequent PAD in those without these confounding factors, even in older age (Ix 
et al. 2011).  
Taken together, all the above mentioned differences in the extent and 
severity of atherosclerosis as well as in the CVD risk factor prevalence may 
account for some of the observed differences between these patient groups in 
the current thesis (Papers I and IV). Despite many similarities, PAD and CAD 
patients can differ from each other in the way their inflammatory and meta-
bolomic profiles relate to other biochemical and functional parameters. 
 
 
6.5. Limitations 
The present study (Papers I–IV) has a number of limitations. Firstly, as the 
design of our study is cross-sectional, we were unable to establish causality. As 
such, our data primarily help identify preliminary relationships and generate 
hypotheses for future research. Secondly, only male participants were recruited 
and thus our findings cannot be fully extrapolated to women and younger 
subjects. Thirdly, for ethical reasons, we could not withdraw patients from their 
medications in order to exclude their potential effects on hemodynamic 
parameters and levels of biochemical markers. Also, as smokers were included 
in this study, long-term health consequences of smoking cannot be ruled out. 
However, in order to minimize some of these confounding effects, all subjects 
were studied after an overnight fast and abstinence from tobacco, alcohol and 
caffeine-containing beverages (Papers I–IV).  
It should also be noted that various stenotic arterial segments may have led 
to a considerable underestimation of PWV, particularly in subjects with PAD 
(Papers I and IV). In addition, the urine albumin-to-creatinine ratio, an early 
marker of kidney disease, was not determined in Paper II, but should be 
evaluated in analogous future studies. Finally, we acknowledge that the number 
of participants in our study was relatively small and larger studies are needed to 
confirm our results (Papers I–IV).  
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7. CONCLUSIONS 
1.  Serum fibulin-1 (FBLN-1) concentrations were significantly increased in 
non-diabetic peripheral arterial disease patients compared to clinically 
healthy subjects. Moreover, elevated FBLN-1 levels were independently 
associated with increased aortic augmentation index for these patients, but 
not for patients with coronary artery disease or healthy controls. This extra-
cellular protein also seems to be associated with low-grade inflammation in 
atherosclerosis. Thus, FBLN-1 could serve as a candidate marker for systemic 
vascular damage.  
2.  Urinary concentrations of liver-type fatty acid-binding protein (L-FABP) 
and kidney injury molecule-1 (KIM-1), and serum levels of neutrophil 
gelatinase-associated lipocalin (NGAL) and cystatin C (CysC) did not 
significantly differ between coronary artery disease patients, with an esti-
mated glomerular filtration rate of above 60 ml/min per 1.73 m2, and clini-
cally healthy subjects. Nevertheless, the levels of some of these proteins 
seem to be at least partially related to inflammation. Most importantly,  
L-FABP and KIM-1 were independently associated with aortic stiffness for 
the patient group. Therefore, in subjects with coronary artery disease, 
measurements of these urinary proteins may help to further explore the 
interplay between early alterations in renal function and vascular damage. 
3.  Aortic stiffness was independently associated with serum medium- and long-
chain acylcarnitines for patients with coronary artery disease. Serum 
palmitoylcarnitine and carnitine palmitoyltransferase I also correlated with 
several hemodynamic parameters in these patients. These findings suggest 
that in addition to the lipid-related classical cardiovascular disease risk 
markers, the intermediates of lipid metabolism, such as acylcarnitines, may 
serve as novel indicators for altered vascular function. 
4.  The lower serum levels of numerous phosphatidylcholines and lysopho-
sphatidyl-cholines were related either to increased arterial stiffness, increased 
resting heart rate or worse endothelial function for peripheral arterial disease 
patients and coronary artery disease patients but not for healthy controls. 
Thus, our results may partially explain the previously reported association 
between decreased circulating concentrations of some of these lipid species 
and higher cardiovascular risk. 
5.  Besides many similarities, peripheral arterial disease patients and coronary 
artery disease patients showed distinct differences in the way their inflam-
matory and metabolomic profiles were related to other biochemical and 
functional parameters. Differences in the extent and severity of athero-
sclerosis as well as in the cardiovascular risk factor prevalence probably 
account for some of the observed dissimilarities between these patient groups.  
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SUMMARY IN ESTONIAN 
Arterite jäikuse metaboloomiline profiil ja varajase 
neerukahjustuse biomarkerid ateroskleroosi korral 
Suure ja keskmise läbimõõduga elastset tüüpi arterite võime kontraheeruda ja 
lõõgastuda toimib füsioloogiliselt olulise puhvrina, mis muundab südametsük-
list tingitud kõrge energiaga pulsatiivse verevoolu pidevaks ja ühtlaseks vere-
vooluks, kaitstes seeläbi organite kapillaaristikku mehhaanilise kahjustuse eest. 
Ateroskleroosi korral (nt. stabiilse stenokardia ja alajäsemete arterite ateroskle-
roosiga haigetel) on arterid jäigenenud, s.t vähenenud on arterite võime vere-
rõhu tõusu mõjul laieneda. Suurenenud arterite jäikus viib muuhulgas südame 
vasaku vatsakese järelkoormuse tõusu, hüpertroofia ning hapnikuvajaduse 
suurenemiseni. Arteriaalse jäikuse hindamise kuldstandardiks peetakse täna-
päeval pulsilaine leviku kiiruse registreerimist aordis. Pulsilaine leviku kiirus 
aordis, st. aordi jäikus, ennustab sõltumatult üld- ja kardiovaskulaarset suremust 
nii erinevates haigusgruppides kui ka üldrahvastikus. 
Muutuseid arterite struktuuris ja funktsioonis seostatakse ka neerufunkt-
siooni langusega. Kuna kliinilises töös laialdaselt kasutatav seerumi kreatiniini 
tase on suhteliselt hiline (48–72t) ja vähespetsiifiline neerukahjustuse indi-
kaator, püütakse leida uusi biomarkereid, mis aitaksid neerukahjustust tuvastada 
võimalikult varajases etapis. Enimuuritud varajase neerukahjustuse uute bio-
markerite hulka kuuluvad muuhulgas neutrofiilide želatinaasiga seotud lipo-
kaliin (NGAL), neerukahjustuse molekul-1 (KIM-1), maksa-tüüpi rasvhappeid 
siduv valk (L-FABP), fibuliin-1 (FBLN-1) ja tsüstatiin C (CysC). Varasemad 
uuringud on näidanud arterite jäikuse sõltumatut seost kroonilise neerupuudu-
likkusega. Siiski on veel vähe andmeid arterite jäigenemise rolli kohta neeru-
kahjustuse tekkes ja arengus. Uute varajase neerukahjustuse biomarkerite ja 
arterite struktuuri- ja funktsiooni parameetrite vaheliste seoste tuvastamine ja 
analüüsimine võimaldab laiendada teadmisi selles valdkonnas.  
Südame- ja veresoonkonna haiguste riski tõstavad lisaks langenud neeru-
funktsioonile ja hemodünaamika muutustele ka süsteemsed metaboolsed nihked 
organismis. Metaboloomika on kiirestiarenev teadusharu, mis võimaldab bio-
loogilise materjali madalmolekulaarsete ühendite (nt aminohapped, peptiidid, 
lipiidid, süsivesikud, nukleiinhapped, rasvhapped) profiili tuvastamise kaudu 
hinnata erinevate haigustega kaasnevaid spetsiifilisi ainevahetuslikke muutuseid 
ehk nn metaboolset sõrmejälge. Uudsete metaboloomiliste andmete sidumine 
juba valideeritud ja kliiniliselt oluliste funktsionaalsete ja biokeemiliste näita-
jatega võib viia nii uute tundlikumate ja spetsiifilisemate biomarkerite kui ka 
tõhusate terapeutiliste sihtmärkide tuvastamiseni. Madalmolekulaarsete ühendite 
roll arterite jäigenemises ja nende seosed teiste hemodünaamiliste parameet-
ritega ateroskleroosiga haigetel on siiani suuresti teadmata. 
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Uurimuse eesmärgid 
Käesoleva töö üldiseks eesmärgiks oli analüüsida arterite jäikuse ja varajase 
neerukahjustuse biomarkerite omavahelisi seoseid ning tuvastada arterite 
jäikuse madalmolekulaarsete ühendite profiil stabiilse stenokardiaga haigetel, 
alajäsemete arterite ateroskleroosiga haigetel ning kliiniliselt tervetel uuritavatel.  
 
Uurimuse täpsed eesmärgid olid järgmised: 
1. Määrata FBLN-1 seerumi taset ja kirjeldada selle seoseid arterite jäikuse ja 
põletiku näitajatega stabiilse stenokardiaga haigetel, alajäsemete arterite 
ateroskleroosiga haigetel ja kliiniliselt tervetel uuritavatel.  
2. Mõõta NGAL ja CysC seerumi tasemeid, L-FABP ja KIM-1 uriini tasemeid 
ning hinnata nende seoseid arterite jäikuse ja põletiku näitajatega stabiilse 
stenokardiaga haigetel (glomerulaarfiltratsioon ≥ 60 mL/min/1.73 m2) ja 
kliiniliselt tervetel uuritavatel. 
3. Uurida atsüülkarnitiinide seerumi tasemete seoseid aordi jäikuse, hemo-
dünaamika ja põletiku näitajatega stabiilse stenokardiaga patsientidel ja 
kliiniliselt tervetel uuritavatel. 
4. Hinnata fosfatidüülkoliinide ja lüsofosfatidüülkoliinide seerumi tasemete 
seoseid arterite jäikuse, hemodünaamika ja endoteeli düsfunktsiooniga sta-
biilse stenokardiaga haigetel ja kliiniliselt tervetel uuritavatel. 
5. Tuvastada ja analüüsida veresoonte funktsionaalsuse ning biokeemilise ja 
metaboloomilise profiili erinevusi ja sarnasusi stabiilse stenokardiaga hai-
gete ja alajäsemete arterite ateroskleroosiga haigete vahel. 
 
Uuringute meetodid 
Uuringualusteks olid 52 stabiilse stenokardiaga meespatsienti, 38 alajäsemete 
arterite ateroskleroosiga meespatsienti (II – IV staadium Fontaine’i järgi) ja 41 
kliiniliselt tervet meest. Arterite jäikust hinnati pulsilaine kiiruse ja pulsilaine 
analüüsi kaudu Tartu Ülikooli Kardioloogiakliiniku Endoteeli Keskuses. 
Neerukahjustuse- ja põletiku biomarkerite ning madalmolekulaarsete ühendite 
seerumi/uriini tasemed määrati Tartu Ülikooli bio- ja siirdemeditsiini instituudi 
biokeemia osakonnas ja Sihtasutus Tartu Ülikooli Kliinikumi Ühendlaboris.  
 
Tulemused ja järeldused 
1. FBLN-1 seerumi tase oli alajäsemete arterite ateroskleroosiga haigetel 
võrreldes kliiniliselt tervete uuritavatega oluliselt tõusnud ning sõltumatult 
seotud arterite jäikusega. Stabiilse stenokardiaga haigete ja kliiniliselt tervete 
uuritavate hulgas ülalmainitud seost ei esinenud. Seerumi FBLN-1 tase oli 
ateroskleroosiga haigetel seotud ka kroonilise põletikuga, mistõttu võib see 
valk tulevikus leida kasutust süsteemse vaskulaarse kahjustuse biomarkerina. 
2. L-FABP ja KIM-1 uriini tasemed ja NGAL ning CysC seerumi tasemed ei olnud 
stabiilse stenokardiaga haigete (glomerulaarfiltratsioon ≥ 60 mL/min/1.73 m2) ja 
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kliiniliselt tervete uuritavate vahel oluliselt erinevad. Küll aga olid L-FABP 
ja KIM-1 uriini tasemed haigete grupis sõltumatult seotud aordi jäikusega, 
mis võib viidata arterite funktsiooni languse ja varajase neerukahjustuse 
omavahelistele seostele.  
3. Stabiilse stenokardiaga haigetel oli aordi jäikus sõltumatult seotud keskmise- 
ja pikaahelaliste atsüülkarnitiinide kõrgema seerumi tasemega. Lisaks korre-
leerusid selles uuritavate grupis seerumi palmitoüülkarnitiin ja karnitiin pal-
mitoüültransferaas I mitmete hemodünaamiliste parameetritega. Ülalmaini-
tud tulemused viitavad, et lisaks traditsioonilistele lipiidide ainevahetuse 
biomarkeritele võivad atsüülkarnitiinid tulevikus kasutust leida veresoonte 
kahjustuse uudsete indikaatoritena. 
4. Mitmete fosfatidüülkoliinide ja lüsofosfatidüülkoliinide madalamad seerumi 
tasemed olid stabiilse stenokardiaga haigetel ja alajäsemete arterite atero-
skleroosiga haigetel, aga mitte kliiniliselt tervetel uuritavatel, seotud suure-
nenud arterite jäikuse, südame löögisageduse ja endoteeli düsfunktsiooniga. 
Seega võivad need tulemused vähemalt osaliselt selgitada varasemates 
uuringutes leitud seoseid kõnealuste lipiidide madalama seerumi/plasma 
taseme ja kõrgema südame- ja veresoonkonna haiguste riski vahel. 
5. Stabiilse stenokardiaga haigete ja alajäsemete arterite ateroskleroosiga hai-
gete põletiku biomarkerite ja metaboloomilise profiili seoste vahel teiste bio-
keemiliste- ja veresoonte funktsionaalsuse parameetritega esines olulisi 
erinevusi. Selle põhjuseks võivad muuhulgas olla nii ateroskleroosi ulatuse 
ja raskusastme kui ka südame- ja veresoonkonna haiguste riskitegurite 
levimuse erinevused kahe haigete grupi vahel.  
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